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ABSTRACT
A crucial component of the cellular response to stress is the attenuation of
protein synthesis to allow the cell to dedicate resources for the restoration of
homeostasis or towards the induction of apoptotic cell death in case the stressors
overwhelm the cell. This process is itself regulated by one of the four eIF2α kinases of
which PKR (Protein Kinase R) is responsible for inhibiting general translation during viral
infection, oxidative stress, ER stress, heat shock or serum withdrawal.
During viral infection, PKR is transcriptionally induced by interferon but remains
latent until it interacts with dsRNA. This interaction induces a conformational change
that activates PKR’s catalytic activity, resulting in the phosphorylation of the eukaryotic
initiation factor eIF2α and the cessation of both general and viral protein synthesis. This
inhibition of viral protein synthesis is however short-lived, as several viral and host
cellular factors are coopted by viruses to neutralize PKR’s catalytic activity against viral
replication. One such cellular factor is PACT (Protein Activator of PKR), PKR’s protein
activator during non-viral stress, which interacts strongly with PKR during HIV infection
but does not activate its catalytic activity. We investigated the mechanisms behind
PACT’s inability to activate PKR robustly during HIV infection. Our results show that
PACT acts synergistically with the HIV trans-activator, Tat, dsRNA-containing mRNAs, as
well as the adenosine deaminase, ADAR1 to form a PKR inhibitory complex to facilitate
the translation of viral mRNAs during HIV infection. Most importantly, these results
vi

elucidate a pathway that could be a target of antiviral therapy to promote PKR
activation and reduce viral load in infected cells.
During non-viral stress, PKR’s activity is regulated negatively by the TAR RNA
Binding Protein, TRBP. TRBP regulates PKR activity by interacting with PKR as well as
PACT. Stress-induced phosphorylation of PACT at Serine 287 weakens its interaction
with TRBP, while increasing PACT’s homomeric interactions and heteromeric
interactions with PKR. The role, if any, of similar stress-induced post-translational
modifications on TRBP’s ability to form homomeric interactions and heteromeric
interactions with PKR as well as to inhibit PKR have remained unclear. In this light, we
investigated whether TRBP is subject to stress-induced phosphorylation and how that
might alter TRBP-TRBP and TRBP-PKR interactions as well as TRBP’s ability to inhibit PKR.
Our results demonstrate that TRBP is phosphorylated by the Mitogen Activated Protein
Kinases JNK and ERK in response to oxidative stress, and consequently forms strong
homomeric interactions with PKR, resulting in increased inhibition of PKR and better cell
recovery during oxidative stress.
PKR, PACT, and TRBP ‘s homomeric and heteromeric interactions are primarily
mediated by the evolutionarily conserved dsRNA binding motif (dsRBM) present in all
three proteins as well as in several other dsRNA binding proteins. We investigated the
contributions of the two copies of dsRBMs in PACT to PACT’s interactions with dsRNA,
PACT, TRBP, and PKR. Our results establish that each motif contributes to a varying
extent towards PACT’s interaction with its known binding partners, and highlight the
importance of PACT homodimerization for PKR activation.
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CHAPTER 1

INTRODUCTION1

1

To be adapted into a comprehensive review titled: ‘The double-stranded RNA binding proteins
PACT, PKR, and TRBP – diverse roles in cellular stress, innate immunity, and RNA interference’
Chukwurah, E., and Patel RC. Manuscript in preparation.
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1.1 THE EIF2A KINASES: MASTER REGULATORS OF PROTEIN SYNTHESIS
DURING CELLULAR STRESS
Eukaryotic cells encounter a diverse array of stressful conditions and must
respond in each situation such that the cells ensure their survival while limiting the
deleterious effects of the stressor. These stressful conditions, which range from viral
infection to the accumulation of misfolded proteins in the cell’s endoplasmic reticulum
(ER), elicit a coordinated response in eukaryotic cells termed the Integrated Stress
Response (ISR)1.
The focal point of the ISR, which is an evolutionarily conserved signaling pathway
induced in response to various stress signals, rests on the attenuation of general protein
synthesis and the preferential translation of mRNA transcripts encoding proteins
essential for ameliorating the stressful conditions 2,3. The ISR is also responsible for
inducing apoptosis if the stressful conditions overwhelm the cell. The entire stress
response pathway is initiated by the phosphorylation of the α-subunit of the eukaryotic
initiation factor (eIF2) by one of four dedicated eIF2α kinases 4–8.
During the initiation of protein synthesis, eIF2 forms a ternary complex with GTP
and the methionyl charged initiator tRNA (Met-tRNAi). The ternary complex
subsequently associates with the 40S small ribosomal subunit and other initiation
factors to form the 43S pre-initiation complex (PIC). The 5’m7-G-cap binding initiation
factor complex eIF4F facilitates the interaction of the mRNA transcript with the newly
formed PIC, and the PIC scans the 5’UTR of the mRNA transcript until it encounters the
AUG start codon. At this point, the 60S large ribosomal subunit associates with the
2

mRNA transcript and the PIC to initiate the translation of the mRNA transcript. This
results in the hydrolysis of the eIF2-bound GTP to GDP, and the release of eIF2-GDP
from the ribosome so another round of protein translation can commence 1.
The eIF2α kinases effectively inhibit protein synthesis by phosphorylating eIF2’s
α subunit (eIF2α). The eIF2 protein consists of three subunits, eIF2α, -β, and -γ. Active
eIF2 has a non-phosphorylated eIF2α and low affinity to the guanine nucleotide
exchange factor eIF2B. In that state, eIF2B exchanges GDP to GTP from the eIF2γ
subunit, ensuring its active state. Non-phosphorylated eIF2α, eIF2β, GTP-loaded eIF2γ,
methionyl tRNA (Met-tRNAi), and eIF5 form the ternary complex. Upon start site
recognition, eIF2 and eIF5 dissociate from the complex and translation initiation and
elongation ensue. eIF2α phosphorylation at Serine 51 increases its affinity for eIF2B and
eIF59, thereby reducing the guanine nucleotide exchange factor that slows down the
formation of the ternary complex, resulting in the attenuation of protein translation
initiation (Figure 1.1.) The decreased abundance of the ternary complex consisting of
eIF2, GTP, and the methionyl-charged initiator tRNA leads to the preferential translation
of mRNAs encoding stress-responsive proteins i.e. the transcription factors ATF4 10 and
CHOP11,12, and protein phosphatase regulatory subunit GADD34 13 due to alterations in
translation initiation at multiple upstream open reading frames (uORFs) in the 5’
untranslated region (5’ UTR) of these mRNAs.
These transcription factors stimulate the expression of proteins which include
chaperones, antioxidant proteins, or proapoptotic proteins among others to ensure
cellular recovery or induce apoptosis if stress signals are sustained14–17. The GADD34
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protein interacts with the catalytic subunit of protein phosphatase 1 (PP1) to trigger
eIF2α dephosphorylation and promote ISR termination 13. The duration and extent of
the stress response is regulated by several feedback mechanisms. For instance, ATF4
regulates the transcription of GADD34, which is essential for translational recovery
towards survival, and of CHOP 18, whose accumulation plays a pivotal role in converting
the stress response from an adaptive phase to apoptosis when the ISR is overwhelmed.
Many laboratories over several years have characterized each of the four eIF2α kinases
and the specific stress signals that lead to their activation and consequent inhibition of
general protein synthesis3. The specificity of activation of each kinase in response to
stress signals is conferred by the presence of varied regulatory domains flanking a
common homologous kinase domains. These regulatory domains mediate the kinases’
homodimerization, autophosphorylation, activation and eventual phosphorylation of
eIF2α (Figure 1.2.)
General control nonderepressible 2 (GCN2), which has the distinction of being
the only eIF2α kinase conserved in almost all eukaryotes, is activated during amino acid
deprivation, and contains, in addition to its kinase domain, regulatory domains
consisting of RING finger and WD repeat (RWD), pseudokinase, histidyl tRNA
synthetase-like (HisRS-like), and dimerization/ribosome binding domains. These
domains together mediate the interaction between GCN2 and uncharged tRNAs,
resulting in GCN2 homodimerization, trans-autophosphorylation and eIF2α
phosphorylation19,7,20,21.
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The PKR-like ER resident kinase (PERK) is activated in response to the
accumulation of misfolded proteins in the endoplasmic reticulum (ER) and is essential
component of the Unfolded Protein Response (UPR)22,23. In line with this function as a
sensor of ER stress, PERK contains an ER luminal domain that associates with the ERresident chaperone Bip/Grp7824. Increased association of misfolded proteins with Bip
during ER stress causes its dissociation from PERK’s luminal domain and results in the
dimerization and activation of PERK’s C-terminal cytoplasmic kinase domain, and
inhibition of protein synthesis.
The Heme Regulated Inhibitor (HRI) kinase is responsive to the presence of
heme, which is essential to globin synthesis in erythroid cells. HRI possesses two hemebinding sites; the first of which is in HRI’s N-terminus, and the second inserted within
HRI’s kinase domain. This second heme binding is essential to ensure HRI’s activation in
response to heme deficiency, as the reversible binding of heme to this site when heme
is abundant within the cell prevents HRI activation, resulting in eIF2α phosphorylation
and the cessation of globin synthesis6,25,26.
Protein Kinase R (PKR) is the primary eIf2α kinase activated in response to viral
infection in the cell. To that effect, PKR contains evolutionarily conserved doublestranded RNA binding motifs (dsRBMs) which mediate its interactions, not only with
dsRNA generated during viral infection, but also with other dsRBM containing proteins.
PKR is also activated in response to non-viral cellular stress which includes stress
resulting from the accumulation of misfolded proteins in the ER, reactive oxygen species
(oxidative stress), heat shock, and serum deprivation. Additionally, various studies have
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shown that PKR is also important for the optimal activation of transcription factors in
key cellular signaling pathways such as ATF327, IRF128, NF-κB29,30, and p5331 among
others32.
As such, PKR and PKR-mediated signaling pathways have been implicated in
several cellular processes such as mitotic regulation and inflammation through NF-κB
signaling and in human pathological conditions ranging from diabetes to several
neurological and neurodegenerative diseases33,34.
In this chapter, we describe PKR’s structure and the mechanisms by which it is
activated during viral and non-viral stress through its interaction with dsRNA and the
stress-regulated protein, PACT. We also describe the importance of protein-protein
interactions and stress-induced post-translational modifications of PACT as well as the
dsRNA binding protein, TRBP, in activating or inhibiting PKR’s activity during cellular
stress.

1.2 THE INTERFERON INDUCED EIF2A KINASE, PKR
Cells employ both cytoplasmic and cell-surface pathogen-recognition receptors
to recognize a wide range of pathogens and their molecular products. The association of
these Pathogen associated molecular patterns (PAMPs)35,36 with their cognate receptors
induces the secretion of cytokines known as interferons (IFNs)37,38 which bind to
receptors on the target cell to induce the expression of genes termed Interferon
Stimulated Genes (ISGs). These ISGs encode proteins with potent antiviral activity
targeting several aspects of viral replication in host cells39,40.
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Separate groups of researchers independently observed that synthesis of both
host and viral proteins in IFN-treated reovirus41, or encephalomyocarditis virus42
infected cells as well as in IFN and dsRNA-treated cells were significantly diminished.
These observations added inhibition of protein synthesis to the growing list of IFNinduced antiviral activities, and raised questions about the identity of the specific IFN
induced translational inhibitor. Previous studies performed with HRI, then a recently
characterized eIF2α kinase in rabbit reticulocytes, led researchers to believe that this
IFN-induced factor was an eIF2α kinase particularly sensitive to the presence of
dsRNA19.
Autoradiographs of γ-32P ATP labelled proteins from dsRNA and IFN treated cells
showed bands at ~67 kDa and ~35 kDa respectively that increased in intensity with
increasing dsRNA concentrations indicative of protein phosphorylation. Further
experiments confirmed that the increased intensities of the 67 kDa (PKR) and 35 kDa
(eIF2α) bands were due to increased PKR autophosphorylation and subsequent eIF2α
phosphorylation, while northern and western blot analyses showed steady increases in
PKR mRNA transcript and protein levels with IFN-α exposure43. These findings
demonstrated that PKR is the IFN-induced eIF2α kinase responsible for the inhibition of
viral mRNA translation.
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1.2.1 PKR’s DOMAIN STRUCTURE: DSRNA BINDING MOTIFS AND EIF2 ALPHA KINASE
DOMAIN
PKR, like the other eIF2α kinases, is a serine-threonine kinase responsible for
phosphorylating eIF2α on Serine 51. A direct comparison of PKR’s 551 amino acid
sequence with those of other eIF2α kinases as seen in Figure 1.2 places PKR’s kinase
catalytic domain at its C-terminus (residues 165 – 551). This was confirmed by
experiments using a mutant PKR protein in which the C-terminus had been deleted;
while the expression of full length PKR in Saccharomyces cerevisiae induced an
inhibitory growth phenotype, the mutant protein was unable to produce a similar effect
on the yeast cells’ growth. This mutant protein also retained its dsRNA binding
properties, indicating that PKR’s regulatory dsRNA binding domain was located at its N
terminus (residues 1-64).
Further characterization of PKR’s N-terminal dsRNAs binding domain (dsRBD)
indicated that this domain was comprised of two tandem dsRNA binding motifs;
dsRBM1 (residues 10 -72) and dsRBM2 (residues 100 -165), separated by a flexible 20amino acid long linker sequence44. Like dsRBMs in other dsRNA binding proteins, PKR’s
dsRBMs have been shown to possess an α-β-β-β-α fold with the α-helices lying on one
face of a three-stranded antiparallel β-sheet.
These α-helices are amphipathic in nature as they are primarily made up of basic and
hydrophobic residues on opposite sides of the helices. Some of the basic amino acids in
these helices were shown to be important for dsRNA binding, as targeted mutations of
several of those residues (K60, K61, K64, and K69) were shown to disrupt PKR binding to
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dsRNA through a poly I:C agarose binding assay, with some mutations directly affecting
PKR activation45–47. Together with the random coiled 20-amino acid linker, these basic
amino acid residues have been proposed to wrap around the target dsRNA and establish
essential electrostatic interactions with the 2’-OH groups and negatively charged
phosphate backbone of the dsRNA to ensure optimal PKR-dsRNA binding, resulting in
efficient PKR activation48.
The amphipathic α-helical structures in PKR and other proteins have been shown
to play key roles in the proteins’ dimerization, and accordingly mediate PKR’s
dimerization through mutational analysis. Mutations of hydrophobic residues in PACT’s
α-helices necessary for PKR dimerization destroyed PKR’s ability to phosphorylate eIF2α
and inhibit yeast growth, demonstrating that PKR dimerization is important for PKR’s full
enzymatic activity49.
On the other hand, structural analysis of PKR’s C-terminal kinase domain showed
that it consisted of an ATP binding pocket flanked on either side by an N-terminal and Cterminal lobe. Mechanistic studies of dsRNA-PKR binding show that dsRNA binding to
PKR induces a conformational change in PKR that exposes the ATP binding pocket such
that PKR can trans-autophosphorylate itself50,51, become activated and then
phosphorylate eIF2α on Serine 51.
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1.3 REGULATION OF PKR ACTIVITY DURING VIRAL AND NON-VIRAL CELLULAR
STRESS: DSRNA, HEPARIN, PACT AND TRBP
1.3.1 PKR ACTIVATION BY DSRNA AND HEPARIN
dsRNA remained the most well-characterized and recognized PKR activator until
studies demonstrating PKR activation in response to other cellular conditions without
dsRNA spurred the search for other cellular PKR activators. Due to the nature of PKR’s
interaction with polyanionic dsRNA, researchers used in vitro kinase activity assays to
test the ability of other polyanionic molecules such as dextran sulfate and chondroitin
sulfate to activate PKR in the absence of dsRNA52. All the compounds that were tested
induced PKR activation, but the highest PKR activity was observed when the assay was
performed using the polyanionic glycosaminoglycan, heparin46,52,53. Heparin is a
polysaccharide synthesized and secreted by mast cells and basophils and made up of
alternating sulfated glucosamine with glucuronic or sulfated iduronic acid units.
Based on previous findings that showed strong PKR activation by heparin in vitro,
researchers investigated heparin’s ability to activate PKR in vivo and the effects of this
event on VSMC proliferation54. They found a significant increase in PKR activation in
heparin-treated VSMCs correlative with increased PKR-heparin interaction, and noted
that the absence of PKR, observed with cell cycle analysis of PKR null (PKR -/-) and wild
type (PKR +/+) MEFs, was sufficient to negate the anti-proliferative effects of heparin
treatment54. These results were recapitulated in rat primary aortic vascular smooth
muscle cells (RASMCs) transfected with the dominant negative PKR mutant, K296R PKR,
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where inhibition of PKR partially rescued the G1-to-S transition block55. Taken together,
these results established PKR as a key effector of heparin’s anti-proliferative activity.
Based on the comparable properties of heparin and dsRNA, it was expected that
the mechanism by which heparin induced PKR activation would also involve interaction
with PKR’s N-terminal dsRBMs. Intriguingly, researchers observed that in vitro kinase
assays performed with N-terminal PKR deletion mutants and wt PKR showed
comparable levels of PKR autophosphorylation and eIF2α phosphorylation with
heparin56. Later work also demonstrated that pre-incubation of PKR with heparin
blocked subsequent PKR activation by dsRNA and heparin did not out-compete the
adenovirus VAI dsRNA for binding to PKR57. All these findings suggested that heparin
associated with PKR at a different site than the expected dsRBD, and conformational
changes induced by heparin precluded the activation of PKR’s kinase activity by dsRNA
interaction with PKR’s dsRBD. More importantly, these findings clearly indicated that
heparin induces PKR activation by an alternative mechanism involving heparin’s
interaction with PKR’s C-terminal kinase domain.
Deletion mapping of PKR’s heparin interaction domains showed that two regions
designated ATD (residues 279 - 318) and CTD (412 - 479) within PKR’s C-terminal kinase
domain were crucial to heparin-PKR interaction and heparin-induced PKR activation56.
Further characterization of the heparin interacting domains revealed the presence of a
positively charged binding cleft conducive to heparin binding57, and provided evidence
for a mechanism of PKR activation in which heparin associates with PKR monomers and
induces a conformational change to facilitate dimerization and PKR activation.
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1.3.2 PKR ACTIVATION BY PACT
The specific circumstances required for PKR’s activation by heparin led
researchers to continue to search for other cellular activators that could account for PKR
activation in other non-viral cellular contexts.
PACT (Protein Activator of PKR), a 313-amino acid long protein, was identified as
a PKR interacting protein in a yeast two-hybrid screen of a human cDNA library using the
trans-dominant negative PKR mutant K296R as bait58. A murine PACT homolog, RAX
(PKR-associated protein X), was also similarly identified in a mouse cDNA library screen
using the catalytically inactive murine PKR homolog (K271R mPKR) as bait59.
A comparison of PACT/RAX’s amino acid sequence to that of PKR and other dsRNA
binding proteins showed that PACT also contained three evolutionarily conserved
dsRBMs (Figure 1.3)
PACT’s first two dsRBMs showed the strongest sequence conservation to PKR’s
N-terminal dsRBD and the first two dsRBMs found in TRBP (TAR RNA Binding Protein),
TRBP’s murine homolog Prbp (Protamine RNA-binding Protein) and the Xenopus dsRBP
Xlrbpa (Xenopus laevis RNA-binding Protein A). PACT/RAX’s ability to recognize and bind
dsRNA were independently confirmed through dsRNA binding assays that showed their
preferential binding to synthetic dsRNA (poly I:C) over dsDNA or ssDNA58,59.
To determine the functional importance of PACT’s interaction with PKR for PKR’s
catalytic activity, investigators performed in vitro PKR activity assays using purified
recombinant PACT and immunoprecipitated PKR. Similar to results obtained with
previously characterized PKR activators, the addition of increasing amounts of PACT
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resulted in a corresponding increase in PKR’s kinase activity, after which higher PACT
concentrations resulted in PKR inhibition58.
Further evidence that PACT could efficiently activate PKR in the absence of dsRNA was
provided by in vitro kinase assays performed with recombinant PACT purified to remove
associated dsRNA and in vivo yeast growth inhibition assays58. In the former set of
experiments, the results demonstrated that PACT strongly activated PKR in the absence
of dsRNA and could even activate PKR point mutants defective in activation by dsRNA
(K150A PKR, and A158D PKR), indicating that PKR association with dsRNA was
inconsequential to PACT-mediated PKR activation.
The latter set of experiments supported results from the first set of experiments,
as investigators observed a marked reduction of yeast growth in cells co-expressing
PACT and wt PKR. Like the previous results, PACT was still able to enhance PKRmediated yeast growth inhibition in yeast cells expressing the dsRNA-binding defective
PKR point mutants, showing that this activation was independent of dsRNA binding.
The results from these experiments showed that PACT retained its ability to strongly
activate PKR in the absence of dsRNA or PKR’s dsRNA binding ability, establishing PACT
as a PKR-interacting protein that could activate PKR in response to non-viral cell stress.
Considering the evidence pointing towards PACT as a potential cellular activator of PKR,
it became necessary to identify the specific cellular conditions that required PACT for
efficient PKR activation in vivo, as well as the domains of PACT necessary for mediating
its interaction with PKR and PKR’s consequent activation.
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PACT ACTIVATION OF PKR DURING NON-VIRAL CELLULAR STRESS: DSRBM-MEDIATED
INTERACTIONS AND REQUIREMENT OF STRESS-INDUCED PACT PHOSPHORYLATION FOR
EFFICIENT PKR ACTIVATION.
To investigate PACT’s role in enhancing PKR activation in vivo, mammalian cells
were transiently transfected with PACT and subsequently assessed for changes in
translation, PKR autophosphorylation, and eIF2α phosphorylation. Results indicated that
PACT overexpression significantly enhanced PKR activation and consequently eIF2α
phosphorylation, resulting in a ~2-fold increase in protein translation inhibition
compared to cells expressing an empty vector58. Cells overexpressing PACT/RAX also
demonstrated an increased sensitivity to cellular stress and apoptosis59,60 resulting from
serum starvation, exposure to hydrogen peroxide, sodium arsenite and inflammatory
cytokines59–61. In contrast, PACT overexpression in PKR -/- MEFs had a marginal effect on
stress-induced apoptosis60, indicating that PACT primarily exerted its effects on PKR in
response to stressful cellular conditions.
These results were recapitulated in PACT -/- and PKR -/- MEFs treated with
tunicamycin, a reagent which induces the unfolded protein response and ER stress in
cells by inhibiting N-linked glycosylation of nascent proteins62. Reconstitution of PACT or
PKR restored tunicamycin-induced apoptosis, eIF2α phosphorylation, as well as
downstream induction of CHOP expression, implicating PACT in PKR’s response to ER
stress62. Taken together, these findings provided conclusive evidence that PACT is
responsible for the efficient activation of PKR in response to a diverse range of non-viral
cellular stressors.
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PACT INTERACTION WITH PKR – DSRNA BINDING MOTIF MEDIATED INTERACTIONS
Co-immunoprecipitation assays with in vitro synthesized PACT and PKR or PKR’s
N-terminal dsRNA binding domain showed that PACT directly interacted with PKR, and
specifically with PKR’s dsRBD, as no direct interaction was observed between PKR’s Cterminal kinase domain and PACT58.
With noted similarities between two of PACT’s dsRBMs and PKR’s own dsRBMs,
experiments were performed to determine which of PACT’s three dsRBMs were
absolute requirements for PKR interaction and activation were by successively deleting
each PACT dsRNA binding motif. Co-immunoprecipitation assays with full length PKR
and the various PACT deletion mutants demonstrated that while each individual motif
was unable to co-immunoprecipitate PKR, the PACT mutant lacking the M3 motif
retained PACT’s ability to interact with PKR63,64, demonstrating that PACT’s M1 and M2
cooperated with each other to ensure PACT’s interaction with PKR.
Having determined that PACT’s interaction with PKR is primarily mediated by the
M1 and M2 motifs, in vitro translation inhibition assays and apoptosis assays in cells
transfected with the PACT deletion mutants were subsequently performed to
characterize the contribution of each motif to PKR activation. While the PACT deletion
mutants lacking the M1 and M2 motifs showed similar levels of enhanced PKR-mediated
translation inhibition of a luciferase reporter and induction of apoptosis, removal of
PACT’s M3 motif completed abolished both effects. In vitro kinase assays performed
with these mutants showed also that the M3 motif alone induced PKR activation
strongly, which the other two motifs were unable to do. However, when cells were
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transfected with a PACT M3 deletion expression construct, this PACT mutant was unable
to activate PKR in vivo, suggesting that while the M3 motif is essential for PACT’s
activation, the M1 and M2 motifs contribute in vivo to PACT’s ability to activate PKR63.
This suggestion was borne out by independent experiments performed with
chimeric proteins consisting of PACT’s M3 motif and PKR’s dsRBD or TRBP’s two dsRNA
binding motifs65. While both proteins’ dsRBDs had previously been shown to inhibit PKR
activity, the addition of PACT’s M3 motif to each domain led to PKR activation,
indicating that the M3 motif confers PKR activation abilities to PACT and PACT-PKR
heterodimerization conferred by PACT’s first two dsRBMs is important to ensure PACT’s
activation of PKR in vivo.
Interestingly, while in vivo co-immunoprecipitation assays showed strong interaction
between PACT/RAX and PKR in stressed cells, the interaction between PACT and PKR is
markedly reduced although not completely absent. This indicated that specific stressinduced changes such as posttranslational modifications may be responsible for the
stronger in vivo interactions.

ROLE OF STRESS-INDUCED PACT PHOSPHORYLATION IN EFFICIENT PKR ACTIVATION
DURING NON-VIRAL CELLULAR STRESS
Initial insights into the regulation of PKR activity via stress-induced PACT
phosphorylation were provided by two different studies; in the first study, the authors
observed a stress-dependent rapid enhancement of RAX-PKR interaction that correlated
with an increase in eIF2α phosphorylation in IL-3 dependent cells deprived of IL-3 or
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treated with thapsigargin, sodium arsenite, or hydrogen peroxide59. Anti-RAX
immunoblotting performed after isoelectric focusing of protein extracts from the
examined cells revealed the presence of a banding pattern consistent with stressinduced RAX phosphorylation59. In the second study, investigators exposed cells to
sodium arsenite or hydrogen peroxide to activate PKR, and observed a similar stressdependent increase in PACT-PKR association over the course of treatment60. In vivo 32Porthophosphate labeling of PACT in the treated cells also showed that the observed
increase in PACT-PKR interaction coincided with increased PACT phosphorylation 60.
Interestingly, both studies demonstrated that PACT/RAX phosphorylation preceded
eIF2α phosphorylation in response to cellular stress induced by IL-3 deprivation or
treatment with hydrogen peroxide, sodium arsenite or thapsigargin.
These results led both sets of investigators to conclude that stress-induced PACT/RAX
phosphorylation increased the interaction between PACT and PKR to enhance PKR
activation and consequently PKR-mediated eIF2α phosphorylation in response to nonviral cellular stress.
Given that PACT’s M3 motif had been demonstrated to be crucial for PKR
activation and increased PACT-PKR heterodimerization and PKR activation is always
accompanied by stress-induced phosphorylation of PACT, Li and colleagues set about
identifying candidate serine residues in PACT’s M3 motif that could be phosphorylated
in response to stress66. Alanine-scanning mutagenesis identified four of these residues
(S246, S265, S279, S287) of which two (S246, S287) were unable to induce PKR
activation and consequently apoptosis. Substitution of threonine or aspartic acid for

17

alanine in the S246A and S287A mutants restored their ability to induce apoptosis in
transfected cells and activate as well as bind PKR.
Results from further biochemical analysis of purified PACT from stress and
unstressed cells revealed the presence of three differentially phosphorylated PACT
isoforms. Researchers observed that PACT was either unphosphorylated or partially
phosphorylated when purified from unstressed cells, and exposure of these cells to
stress resulted in a significant increase in a fully phosphorylated PACT isoform.
Intriguingly, the researchers also observed that the S246A PACT mutant exhibited only
the unphosphorylated PACT isoform while the S287A PACT mutant exhibited both the
unphosphorylated and partially phosphorylated PACT isoforms before and after stress.
These results established that PACT is constitutively phosphorylated at S246 in the
absence of stress, and becomes phosphorylated at S287 in response to stress signals
leading to the observed increased interaction between PACT and PKR and subsequent
PKR activation.

ROLE OF PACT HOMODIMERISATION IN EFFICIENT PKR ACTIVATION DURING NON-VIRAL
CELLULAR STRESS
Since PKR dimerization had already been shown to be important to PKR
activation, it was unclear as to whether PACT’s ability to activate PKR was equally
dependent on its ability to dimerize, and if stress-induced PACT phosphorylation had
any role in inducing this dimerization. Yeast two-hybrid assays were subsequently
performed to identify the PACT motifs required for PACT-PACT dimerization, and results
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showed that while PACT’s M1 and M2 motifs could interact with each other (M1-M1,
M1-M2, M2-M2), PACT’s M3 motif was only able to interact with itself (M3-M3). As
PACT’s M3 motif had already been shown to contain two phosphorylation sites (S246,
S287) crucial to PACT’s activation of PKR, the specificity of the M3-M3 motif interaction
strongly suggested that M3-M3 motif interaction could be enhanced during stress to
enhance PACT-PACT interaction and consequently, PACT-PKR interaction and PKR
activation. Increased homomeric PACT-PACT interactions in response to stress signals
were supported by yeast two-hybrid experiments with phosphorylation-mimetic (PACT
S246 S287D) and phosphorylation-defective (S246A S287D) PACT point mutants67.
The importance of the observed PACT homodimer formation in PACT-mediated
PKR activation in response to stress was clearly demonstrated in experiments with a
dimerization-deficient PACT mutant (L99E PACT) which retained its ability to interact
with PKR. While wt PACT, dsRNA, and heparin robustly activated PKR, L99E PACT was
unable to activate PKR efficiently, indicating that PACT dimerization was necessary for
efficient PACT-mediated PKR activation68.
While the studies with PACT phosphorylation-defective and mimetic mutants
underscored the importance of stress induced PACT-PACT and PACT-PKR interaction and
reduced PACT-TRBP mediated through residues in PACT’s M3 motif, the individual
contributions of PACT’s M1 and M2 motifs to PACT’s ability to interact with dsRNA as
well as with itself, PKR and TRBP have remained unclear and have been elucidated in
Chapter 4 of my dissertation.
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PACT AND PKR DURING VIRAL INFECTION
In addition to its established role in the PKR-mediated stress response pathway,
PACT has also been shown to be involved in a steadily increasing number of key cellular
pathways, such as small RNA biogenesis69–72 during RNA interference via interaction
with the Dicer protein and the cellular innate immune response to viral infection via
interaction with pattern recognition receptors RIG-I and MDA-573,74.
A possible antiviral function for PACT was first presented in a study in which
siRNA PACT/RAX-depleted MEFs were infected with vesicular stomatitis virus (VSV).
These VSV-infected cells exhibited significantly increased viral titers and viral protein
synthesis as well as decreased eIF2α phosphorylation levels compared to the wildtype
cells61. These results suggested then that in addition to its role as a PKR activator during
non-viral stress, PACT could also enhance PKR’s antiviral activity or possess an inherent
antiviral function independent of PKR activation. A subsequent study involving L929
cells infected with the Newcastle disease virus (NDV) demonstrated that PACT
expression could in fact stimulate IRF3 and IRF7 activity in these cells in a PKR
independent manner, resulting in IFN-β expression and increased IFN-β enhancer
reporter activity75. PACT was also shown to be directly involved in enhancing the RLRmediated response to viral infection by interacting directly with the cytoplasmic RNA
sensor, RIG-I, during Sendai virus infection73. PACT’s interaction with RIG-I’s CTD
stimulated RIG-I’s ATPase activity and facilitated the production of IFN in the Sendaivirus infected cells as indicated by decreased viral plaque formation with PACT and RIG-I
co-expression73.
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As a well-characterized activator of PKR in response to cellular stress, it was
interesting to study PACT’s ability to activate PKR during HIV infection. A 2013 study of
PACT’s role during HIV infection revealed a significant increase in PACT-PKR interaction
as well as between PACT, PKR, and another dsRNA binding protein, ADAR1, coincidental
with a decrease in PKR activity over the course of viral infection76. An ISG product,
ADAR1 (Adenosine Deaminase Acting on RNA 1) is an RNA-editing enzyme that catalyzes
the deamination of adenosine to inosine in dsRNA substrates, which in turn leads to the
destabilization of RNA secondary structure or the erroneous incorporation of amino
acids detrimental to viral protein structure and function77. Thus, ADAR1 can work in an
anti-viral manner, but HIV specifically seemed to target ADAR1 to inactivate its anti-viral
functions and replicate efficiently78. siRNA mediated knockdown of either PACT or
ADAR1 in HIV infected cells was sufficient to restore PKR-mediated viral replication
inhibition, suggesting that both proteins act synergistically to enhance viral replication,
and more importantly, it was suggested that PACT could in fact inhibit PKR’s activity in
HIV-infected cells76. Questions however remained from this study about the
mechanisms underlying this dramatic change in PACT’s ability to activate PKR. Chapter 2
of my dissertation aims to fill this gap and elucidates the mechanism of ADAR1 –
mediated inactivation of PACT-induced PKR activation during HIV replication79.

1.3.2 PKR INHIBITION BY TRBP
As a key effector of IFN’s antiviral activities, PKR is the target of several viral
strategies to limit its inhibition of viral protein synthesis in infected cells. While many of
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these strategies rely on viral factors that may sequester potentially PKR-activating
dsRNAs80,81, act as decoy substrates80,82, or directly interact with PKR83, some strategies
involve the recruitment of cellular host proteins to enhance viral replication,
transcription, and translation by inhibiting PKR84–86.
One such protein is the TAR RNA Binding Protein (TRBP) which was initially
identified as a HIV TAR RNA binding protein in a HeLa cDNA expression library screen
with a TAR RNA probe87. TRBP was subsequently shown to enhance the expression of
reporter genes driven by the HIV-1 LTR, as well as the translation of TAR RNA containing
mRNAs by destabilizing the secondary structure of the dsRNA to allow for greater
translation efficiency. These findings, together with the observation that knockdown of
TRBP expression resulted in dramatically decreased HIV-1 LTR driven gene expression
and viral protein production during active HIV-1 replication88 and viral replication in
astrocytes which express low levels of TRBP was markedly limited89, confirmed that
TRBP is indeed a cellular protein co-opted by the HIV-1 virus to ensure its replication.
TRBP has also been shown to be involved in miRNA biogenesis and RNA induced
silencing through its interaction with Dicer and the RNA induced silencing complex
(RISC)90,91. Mass spectrometric analysis of proteins coimmunoprecipitated with human
Dicer showed an interaction with TRBP, which was also independent of the presence of
dsRNA90. While the initial studies characterizing TRBP’s interaction with Dicer and
functional importance to miRNA processing showed that TRBP depletion had
deleterious effects on miRNA silencing efficiency, subsequent studies have raised
skepticism about the role, if any, that TRBP plays in RNA induced silencing, and if that
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role is simply non-essential92. Questions have also been raised about PACT, which is 40%
similar to TRBP, and whether it serves a redundant function to TRBP and similarly
interacts with Dicer92. Some reports indicate that PACT associates with Dicer to facilitate
miRNA production93,70, while a more recent study shows that TALEN-mediated knockout
of PACT expression has no functional effect on Dicer’s activity or miRNA biogenesis, and
any interaction between PACT and Dicer that was previously observed was attributable
to the fact that the studies were conducted under conditions where PACT was
excessively overexpressed92.
Sequence alignment of TRBP with the amino acid sequences of members of the
double-stranded RNA binding protein family (of which PKR is a member) showed that
TRBP contained three conserved dsRNA binding motifs like PKR’s cellular activator, PACT
(Figure 1.3). Since TRBP and PACT had been shown to interact with the TAR RNA to
different effects on TAR mRNA translation94 and both proteins have similar interacting
partners (i.e. PKR, Dicer), several laboratories sought to uncover the potential regulation
of PKR’s activities during viral replication and cellular stress by TRBP.

TRBP INHIBITION OF PKR DURING HIV-1 INFECTION
During viral infection, IFNs transcriptionally induce the expression of PKR which
remains latent within the cell until it is activated by dsRNA binding. This results in the
inhibition of viral protein synthesis, and consequently, the abrogation of viral
replication. To determine if TRBP could prevent the translational inhibition imposed by
IFN-induced PKR during HIV infection, Benkirane et al infected cells with a chimeric HIV-
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1 virus expressing TRBP, and assayed for changes in viral replication compared to the
cells infected with wild type HIV-1 virus after IFNα treatment95. While the cells infected
with the wild-type HIV-1 virus demonstrated a dose-dependent reduction in viral
replication with IFNα treatment, the cells infected with the HIV-1 virus expressing TRBP
were completely resistant to IFNα, suggesting that TRBP was involved in limiting IFN’s
anti-viral activities in infected cells.
Comparative analysis of HIV protein synthesis in HeLa cells expressing the HIV
genome and transfected with PKR or PKR and TRBP showed that while PKR evidently
reduced the expression of HIV encoded proteins, TRBP significantly blunted PKR’s
inhibition of HIV protein synthesis. Direct detection of viral replication by HIV reverse
transcriptase activity in infected cells transfected with PKR, or co-transfected with PKR
and TRBP showed that TRBP expression boosted viral replication as compared to the
cells infected only with the HIV virus, demonstrating that TRBP directly inhibited PKR
activity to enhance viral replication and protein synthesis. Researchers also observed
that a TRBP mutant devoid of dsRNA-binding inhibited PKR’s activity at similar levels
with wt TRBP, indicating that this inhibitory activity was independent of TRBP’s dsRNA
binding. The interaction of PKR and TRBP was also shown to be independent of dsRNA
interaction, as cellular extracts completely depleted of dsRNA still demonstrated strong
PKR-TRBP interaction, even when the interaction between a dsRNA binding defective
PKR mutant and TRBP was tested. This inhibition of PKR by TRBP in the absence of
dsRNA strongly indicated that TRBP could potentially regulate PKR’s activity during nonviral cellular conditions.
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TRBP INHIBITS PKR’S CATALYTIC ACTIVITY BY INTERACTION WITH PACT
Since PACT had been shown to be primarily responsible for activating PKR in
response to cellular stress, investigators sought to uncover if TRBP could regulate PKR’s
activity through its interaction with its cellular activator, PACT. Co-immunoprecipitation
assays with PACT and TRBP in the complete absence of RNA showed that both proteins
could heterodimerize independently of dsRNA96,58, and subsequent yeast two-hybrid
experiments demonstrated that each protein’s M1, M2 and M3 motifs could interact
with the corresponding protein’s motifs. The effect of such a strong PACT-TRBP
interaction on PKR activity was tested by knocking down TRBP expression in cells
transfected with PACT. PACT overexpression, which normally results in PKR activation
(as detected by phospho-PKR in western blot analysis) was absent in cells expressing
TRBP, whereas stable knockdown of TRBP restored this activity, indicating that TRBP
primarily served to inhibit PKR activity by heterodimerizing with PACT 97.
Since it had been previously established that PACT interacts with and activates
PKR in response to stress signals, it was predicted that PACT would dissociate from TRBP
in response to stress signals to allow for PACT’s association with PKR. This idea was
supported by results from co-immunoprecipitation experiments to assay for changes in
PACT-TRBP interaction in response to hydrogen peroxide and sodium arsenite induced
oxidative stress which showed that PACT-TRBP interaction is disrupted in response to
stress98,67.
Stress-induced PACT phosphorylation at S287 dramatically increases PACT-PACT
homomeric interactions as well as PKR-PACT heteromeric interaction, so experiments
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were performed to test if this phosphorylation event was the trigger for the decrease in
PACT-TRBP heteromeric interaction in response to stress67. As such, yeast two-hybrid
experiments were performed with TRBP and phosphorylation mimetic PACT (S246D
S287D) yeast expression constructs and followed by in vitro and in vivo coimmunoprecipitation assays with S246D S287D PACT and TRBP. In all three experiments,
researchers observed a dramatic reduction in 246D 287D PACT interaction with TRBP as
compared to wt PACT, showing conclusively that stress-induced PACT phosphorylation
increased PACT-PACT and ultimately PACT-PKR interaction and PKR activation by
weakening PACT-TRBP interaction67. The functional importance of a weakened PACTTRBP interaction on PKR mediated apoptosis was demonstrated by analysis of induction
of cell death after PACT (S246D S287D, wt) and TRBP co-transfection into HeLa cells67.
While co-expression of TRBP and wt PACT was sufficient to rescue apoptosis induced by
PACT transfection, TRBP was completely unable to rescue apoptosis induced by
transfection of the S246D S287D phosphorylation mimetic mutant67.
Taken together, the results from these studies showed that TRBP prevents
aberrant PKR activation by forming heterodimers with PACT and upon the receipt of
stress signals due to PACT’s phosphorylation, dissociates from PACT to allow for PACT’s
timely activation of PKR’s kinase activity.

TRBP PHOSPHORYLATION REGULATES PKR ACTIVITY
In addition to its role as a PKR inhibitor during HIV infection and cellular stress, a
recent study indicated that TRBP may also regulate PKR activity during the cell cycle92. In
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one study, investigators noted that mitotic cells showed increased PKR phosphorylation
levels that correlated with increased phosphorylated JNK and eIF2α levels92,99. eIF2α, of
course, is a well characterized substrate of PKR, and JNK is a Mitogen Activated Protein
Kinase (MAPK) whose efficient activation has been shown in several studies to depend
on PKR activation32. This increased PKR phosphorylation during mitosis was shown to be
independent of PACT92, and raised questions about TRBP’s role, if any, in modulating
PKR’s activity during mitosis.
These questions were answered by the cell cycle analysis of TRBP knockout
(TRBP KO) and wildtype cells92; evaluation of both sets of cells showed that the levels of
phosphorylated PKR and eIF2α were significantly elevated and the duration of the G2/M
phase was longer in TRBP KO cells as compared to the wildtype cells. These results, in
addition to a previous finding that PKR overexpression in Chinese Hamster ovary (CHO)
cells induces a similar delay in transition to the G1 phase99, suggested that TRBP could
modulate PKR’s activity during the cell cycle, and consequently affect the cell cycle
transition from the M to the G1 phase.
The western blot analysis of cellular extracts from cells arrested in the G1, S, and
M phases did not show changes in TRBP expression during the cell-cycle, but showed
changes in TRBP phosphorylation92. TRBP was hyperphosphorylated during M phase and
the hyperphosphorylated TRBP isoform was subsequently shown to interact more
strongly with PKR compared to the unphosphorylated S phase TRBP isoform. The
phosphorylated TRBP inhibited PKR’s activation and eIF2α phosphorylation much
strongly than the unphosphorylated isoform. In an intriguing turn, the kinase
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responsible for TRBP’s phosphorylation during mitosis was revealed to be JNK, which is
itself phosphorylated by PKR activated by nuclear dsRNAs during mitosis as the nuclear
membrane disappears. Thus, PKR is involved in a negative feedback loop that promotes
its own inhibition during the cell cycle by facilitating TRBP hyperphosphorylation
through JNK activation92.
Another study also suggested that JNK-mediated TRBP phosphorylation plays a
role in activating PKR during obesity and propagating inflammation in obese animals100,
thereby implicating sustained PKR activation in metabolic disease. These results are
controversial, as another report showed that PKR has no functional role in regulation of
obesity-induced metabolic regulation101. The observed effects in the first study were
deemed to be specific only to the animals used in that study.
Since TRBP phosphorylation has been shown to inhibit PKR’s activity during
mitosis, it is interesting to investigate if, like PACT, TRBP is also phosphorylated in
response to cellular stress and if this phosphorylation event alters the heteromeric
interactions between TRBP and PACT/ PKR to dampen the negative effects of sustained
PKR activation during cellular stress. These aspects were explored in chapter 3 of my
dissertation.

1.4 STRUCTURE OF DISSERTATION
In Chapter 2 of this dissertation, we report the findings of our investigation into
the mechanisms underlying PACT’s inability to activate PKR efficiently despite an
increase in PACT protein levels during active HIV infection. Using a HIV LTR β-
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galactosidase reporter cell line, we found that PACT, like TRBP, enhances the expression
of the LTR-driven reporter in a virally encoded transcription factor (Tat)-dependent
manner at a translational level. Our results establish that PACT, in synergy with Tat,
enhances the translation of HIV TAR-RNA containing transcripts by directly inhibiting
PKR activation. We also demonstrate that the dsRNA binding protein ADAR1 as well as
HIV TAR-RNA are required factors that inactivate PACT-mediated PKR activation. A
complex of PACT-Tat-ADAR1 (and possibly TRBP) formed on TAR-RNA keeps PACT
inactive for PKR activation and facilitates translation of HIV encoded transcripts79.
In Chapter 3, we examine the roles that stress-induced TRBP phosphorylation
plays in regulating PKR activation in response to oxidative stress. Using a tetracyclineinducible TRBP overexpressing HeLa cell line, we demonstrate that TRBP is
phosphorylated in response to sodium arsenite-induced oxidative stress by the MAPKs,
ERK and JNK, and the time-course of this phosphorylation event directly coincides with a
steady decline in PKR and eIF2α phosphorylation and results in a reduction of PKRmediated cellular apoptosis. We also show that the observed decrease in PKR activation
is due to enhanced ability of the phosphorylated TRBP to inhibit PKR. This was further
confirmed by assaying the effect of phosphorylation-mimetic TRBP mutants on the
growth inhibition of yeast cells expressing catalytically active PKR. Finally, protein
interaction studies lead us to conclude that TRBP phosphorylation during oxidative
stress significantly weakens TRBP-TRBP homomeric interactions, which in turn results in
increased TRBP-PKR heteromeric interactions and diminished PKR activity. These
findings provide us with a model for the attenuation of sustained PKR activation and
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induction of cellular apoptosis through increased inhibitory interactions between PKR
and phosphorylated TRBP.
In Chapter 4, we further assess the effects of mutations of conserved
hydrophobic residues in PACT’s M1 and M2 motifs on PACT’s dsRNA binding and
interactions with PACT, TRBP, and PKR. By generating a dsRNA-binding and
homodimerization- defective phosphorylation mimetic point mutant (L99E DD), we
gained insight into how defective homodimerization affects stress-induced PACT-PACT
interaction and PACT-mediated apoptotic induction. These findings together elucidate
the contributions of each of PACT’s dsRNA binding motifs to efficient PACT-PACT, PACTTRBP, and PACT-PKR interaction and highlight the importance of PACT-PACT homodimer
formation to efficient PKR activation in response to cellular stress.
In Chapter 5, we provide general conclusions about the studies presented.
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Figure 1.1: Regulation of eukaryotic translation initiation by the eIF2α
kinases.
The eukaryotic factor eIF2 (made up of α, β, and γ subunits) associates with
GTP and the methionyl-charged initiator tRNA to form a ternary complex.
This complex then associates with the 40S small ribosomal subunit to form a
40S pre-initiation complex, which in turn binds the mRNA transcript as well
as other initiation factors. The onset of translation due to the binding of the
60S large ribosomal subunit is accompanied by the hydrolysis of GTP to GDP.
Another initiation factor, eIF2B which is the dedicated eIF2 GTP exchange
factor (GEF), exchanges the hydrolyzed GDP for GTP so another round of
translation initiation can begin. However, the phosphorylation of eIF2’s α
subunit on Serine 51 by one of the four eIF2α kinases during cellular stress
prevents the exchange factor activity of eIF2B without preventing its
association with eIF2α via eIF2β. This results in the blockage of active eIF2B
as it stays complexed with eIF2α effectively shutting off protein synthesis, as
eIF2B is present in limited quantities within the cell. The resulting decline in
ternary complex formation leads to the cessation of general protein
synthesis1.
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Figure 1.2: Domain structure and activating stimuli of the four eIF2α kinases. Each of the four eIF2α kinases is activated by a
diverse range of cellular stress signals and contain, in addition to a kinase domain, distinct regulatory domains. HRI possesses two
heme binding domain s (HB; depicted in red) one of which is inserted within HRI’s kinase domain (KD I & II; depicted in light blue).
GCN2 has an N-terminal RING finger and WD repeat domain (RWD; depicted in green), a pseudokinase domain (PKD; depicted in
orange), a kinase domain (KD; depicted in light blue), a histidyl tRNA synthetase-like (HisRS-like) domain (His/RS; depicted in grey),
and a C-terminal ribosome binding and dimerization domain (RB; depicted in purple). PERK, the ER resident eIF2α kinase, contains an
N-terminal signal peptide (SP; depicted in green), and ER luminal domain (LD; depicted in orange), a transmembrane domain (TM;
depicted in blue), and a cytoplasmic domain which envelopes its kinase domain (KD; depicted in light blue). PKR, the interferon
induced eIF2α kinase, contains two N-terminal double-stranded RNA binding motifs (dsRBM1 and dsRBM2; depicted in navy blue) in
addition to its C-terminal kinase domain (KD; depicted in light blue).

Figure 1.3: Domain structure of the dsRNA binding proteins, PKR, PACT, and TRBP: All
three dsRNA binding proteins contains multiple copies of the conserved dsRNA binding
motifs. PKR possesses two dsRBMs (M1 and M2; depicted in grey) which mediate PKR’s
interactions with dsRNA as well as with other dsRBM containing proteins. PKR also has a
C-terminal kinase catalytic domain containing a region important for PACT interaction
(denoted by PBM). Two threonine residues (T446, and T451) are the sites of PKR transautophosphorylation required for PKR activation and phosphorylation of eIF2α on
Serine 51. PACT, PKR’s cellular activator contains three dsRNA binding motifs (M1, M2,
M3; depicted here in grey and light blue). Blue arrows depict the serine residues (S246,
S287) identified as stress-induced phosphorylation sites necessary for increased PACT
interaction with PKR and PKR activation. TRBP, an inhibitor of PKR’s activator during
cellular stress and HIV infection, contains three dsRNA binding motifs like those of PACT
(M1, M2, and M3 depicted here in grey and red). Red arrows depict serine residues
(S121, S131, S262, S265) identified as MAPK (JNK/ERK) phosphorylation sites. PACT and
TRBP’s respective M3 motifs confer each protein with their activities as pertains to PKR
activity.
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CHAPTER 2

ADAR1 AND PACT CONTRIBUTE TO EFFICIENT TRANSLATION OF
TRANSCRIPTS CONTAINING HIV-1 TRANS-ACTIVATING RESPONSE (TAR)
ELEMENT2

2
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2.1. ABSTRACT
Human immunodeficiency virus type 1 (HIV-1) has evolved various measures to
counter the host cell’s innate antiviral response during the course of infection.
Interferon (IFN) stimulated gene products are produced following HIV-1 infection to
limit viral replication, but viral proteins and RNA counteract their effect. One such
mechanism is specifically directed against the IFN-induced Protein Kinase PKR, which is
centrally important to the cellular antiviral response. In the presence of viral RNAs, PKR
is activated and phosphorylates the translation initiation factor eIF2α. This shuts down
the synthesis of both host and viral proteins, allowing the cell to mount an effective
antiviral response. PACT (protein activator of PKR) is a cellular protein activator of PKR,
primarily functioning to activate PKR in response to cellular stress.
Recent studies have indicated that during HIV -1 infection, PACT’s normal cellular
function is compromised and that PACT is unable to activate PKR. Using various reporter
systems and in vitro kinase assays, we establish in this report that interactions between
PACT, ADAR1 and HIV-1-encoded Tat protein diminish the activation of PKR in response
to HIV-1 infection. Our results highlight an important pathway by which HIV-1
transcripts subvert the host cell’s antiviral activities to enhance their translation.

2.2: INTRODUCTION
Cells infected with a virus employ a variety of mechanisms to counteract the
negative impact of viral replication and promote cell survival102. The innate immune
response to a viral infection is mediated by external and internal sensor molecules,
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which recognize the viral components as “non-self” and trigger mechanisms leading to
the production of interferons (IFNs)103. IFNs are secreted anti-viral cytokines that bind to
receptors in a paracrine and autocrine manner on cells to trigger signaling cascades
culminating in the expression of IFN-stimulated genes (ISGs)77. Most ISGs have antiviral
functions, although some ISGs with both antiviral and proviral functions have been
recently described78,104,105. Viral and cellular factors regulate ISGs to promote or limit
viral replication respectively and this regulatory interplay between the virus and the
host cell is crucial in determining the outcome of a viral infection. Retroviruses such as
the Human Immunodeficiency Virus type 1 (HIV-1) produce viral factors that interact
with various cellular proteins, including ISGs. As a result, the virus subverts their antiviral properties or co-opts them from their regular cellular activities to facilitate efficient
viral replication within the infected host cell106,107.
One of the ISG products is PKR (protein kinase, RNA-activated), a protein kinase
that plays a central role in regulating the outcome of a viral infection108–110. In virally
infected cells PKR is activated by binding to dsRNA, a product of several viral infections,
including HIV-134,83. The interaction between PKR and dsRNA induces a conformational
change that is essential for PKR’s catalytic activation111. PKR then phosphorylates the
translation initiation factor eIF2α on Serine 51, resulting in a decline of general protein
synthesis, and consequent cessation of viral protein synthesis112,113. In order to
counteract PKR’s antiviral actions, viruses have developed measures that include dsRNA
sequestration, decoy substrates and direct interaction of virally encoded inhibitory
proteins with PKR114,115. One of the host proteins that inhibits PKR activation during HIV-
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1 replication is the TAR RNA Binding Protein (TRBP), which was first identified due to its
strong binding affinity for the Trans-activation response element (TAR) RNA found in the
5’ end of all HIV-1 mRNA transcripts87,116. In eukaryotic mRNAs, the 5’ untranslated
region (UTR) is critical for ribosome recruitment to the mRNA, start codon choice, and
control of translation efficiency. This dual inhibitory effect of TAR on translation has
promoted development of viral countermeasures in order to achieve efficient viral
replication. During HIV-1 infection, TRBP inhibits PKR activation by sequestration of the
activating TAR RNA and by direct interaction with PKR’s two dsRBMs95,117,118. Although
TRBP is an effective inhibitor of PKR, HIV-1 has evolved additional mechanisms to more
effectively block PKR activity and successfully replicate in infected cells109,119.
In the absence of viral infections, basal levels of PKR are present in all cells108. In
uninfected cells PKR regulates responses to oxidative stress, endoplasmic reticulum (ER)
stress and serum starvation97,120. Under these conditions, a cellular Protein Activator of
PKR (PACT) regulates PKR activation121,122. PACT is constitutively phosphorylated on
Serine 246, and is phosphorylated on Serine 287 in response to stress, resulting in
increased homodimerization and PACT-PKR heterodimerization58,60,67. PACT activates
PKR and general protein synthesis is halted, allowing the cell to mount an effective
response to the stressor, or undergo apoptosis if the stressful conditions cannot be
overcome. This stress response pathway is negatively regulated by TRBP, as TRBP
interacts efficiently with PACT in the absence of stress. PACT’s phosphorylation at Serine
287 in response to cellular stress decreases its interaction with TRBP and consequently
PACT-PACT and PACT-PKR interactions increase to activate PKR66,67. Thus, TRBP
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negatively regulates PKR activation during a virus infection, as well as during cellular
stress68.
Recent studies established that PACT’s function as a PKR activator is suppressed
during HIV-1 infection and PACT is unable to activate PKR in HIV-1 infected cells98,109,119.
During the course of HIV-1 infection, there is a transient increase in PKR activation
followed by a gradual decrease, which indicates the presence of a viral mechanism to
subvert sustained PKR activation. A significant increase in the interactions between
PACT, PKR and ADAR1 (Adenosine Deaminase Acting on RNA 1) is observed, and it
strongly correlates with decreased PKR activation and increased viral protein
production98. ADAR1 p150 isoform is an ISG encoded, RNA editing enzyme that catalyzes
the deamination of adenosine to inosine in viral and cellular dsRNA substrates76,123. This
often results in the destabilization of RNA secondary structures or incorporation of
amino acids detrimental to viral protein structure and function78,105,124. In this study, we
further characterized the molecular mechanisms involved in mediating PACT’s proviral
effects during HIV-1 replication. Our findings indicate that PACT increases HIV-1 gene
expression at the translational level via inhibition of PKR activation by acting in concert
with a HIV-1 encoded protein Tat and a cellular protein ADAR1 to bring about sustained
PKR inhibition and efficient translation of TAR-containing mRNAs. This study
underscores the essential role of Tat protein in this inhibitory complex and indicates
that Tat enhances the translation of HIV-1 mRNAs in addition to its canonical
transactivation function during transcription125 and its PKR inhibitory role by acting as a
pseudosubstrate126. Our study also highlights the importance of ADAR1 in this
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multiprotein complex as a key component that mediates PKR inhibition during HIV-1
infection. As all HIV-1 mRNAs contain the TAR structure at their 5’ end, these results
shed light on how these mRNAs are efficiently translated in virally infected cells.

2.3 MATERIALS AND METHODS
2.3.1 CELL LINES AND ANTIBODIES
HeLa MAGI-CCR5 cells127 were obtained through the NIH AIDS Reagent Program.
HeLa-MAGI-CCR5 cells, PKR -/- murine embryonic fibroblasts (MEFs)80, HEK-293T (ATCC
CRL-11268) and HeLa (ATCC CRM-CCL-2) cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% Fetal Bovine Serum and
penicillin/streptomycin. The following antibodies were used: Anti-Flag monoclonal M2
(Sigma), anti-PKR (human) monoclonal (71/10, R&D Systems), anti-V5 (Invitrogen), antiMyc (Santa Cruz).

2.3.2 PLASMIDS
The CMV-TAR-Luciferase/pGL3 basic plasmid was constructed as follows: The
TAR sequence was inserted as an oligonucleotide in the HindIII-BamHI sites of pcDNA3EGFP (Addgene). An 818 bp region containing the CMV promoter followed by TAR was
excised from the TAR pcDNA3-EGFP plasmid described previously and inserted into the
pGL3 basic vector (Promega) at the SmaI-XhoI site upstream of the luciferase coding
sequence. The corresponding CMV-Luciferase pGL3 basic plasmid devoid of TAR was
constructed as follows: A 753 bp region was excised from the pcDNA3-EGFP plasmid and
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inserted into the SmaI-XhoI site upstream of the luciferase coding sequence. The mutant
CMV-TAR-Luciferase/pGL3 basic was constructed by inserting the mutated TAR
oligonucleotide into the HindIII-BamHI sites of pCDNA3-EGFP. The 818 bp region
containing the CMV promoter and mutant TAR sequence was subsequently excised from
the pcDNA3-EGFP expression construct and inserted into the pGL3 Basic vector at the
Sma-XhoI site upstream of the luciferase coding sequence. PACT and TRBP expression
constructs were as described previously60,62. The Tat/pcDNA3 expression construct was
a gift from Dr. Ashok Chauhan128, while the pCMV-Rev and pcDNA3.1-ADAR1-p150-V5
expression constructs were previously described128,129. To generate MycTat/pcDNA 3.1-,
the Tat insert from Tat/pcDNA3 was subcloned into pcDNA 3.1- in order to put a Myc tag
at its amino terminus. pCMV2-Flag-PACT was also previously described62. These
constructs were a gift from Dr. Anne Gatignol (McGill University).

2.3.3 β-GALACTOSIDASE ASSAY
HeLa-MAGI-CCR5 cells were transfected with indicated amounts of the
Tat/pcDNA3, Flag PACT/pcMV2, Flag TRBP/pcDNA 3.1- or only pcDNA 3.1- expression
constructs. β-galactosidase activity was assayed 24 hours after transfection using the
Galacto-Star Assay System (ThermoFisher Scientific).
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2.3.4 SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE PCR
Total RNA was isolated from HeLa-MAGI-CCR5 cells transfected with indicated
amounts of the Tat/pcDNA 3, Flag PACT/pcMV2, Flag TRBP/pcDNA 3.1- or pcDNA 3.1expression constructs. After 2 washes with ice cold PBS, 250 µl of RNAZol B was added
and total RNA was isolated as per the manufacturer’s instructions. cDNA was
synthesized at 42oC for 1 hour using random hexamer primers, 1 µg total RNA, M-MuLV
Reverse Transcriptase, 500 µM dNTPs, and RNase inhibitor RNAsin (Promega). For each
PCR, 2 µl of cDNA and 50 pmoles of forward and reverse primers designed to amplify a
166 bp region of the β-galactosidase transcript or a 500 bp region of the β-actin
transcript were used with the Promega GoTaq Polymerase Kit. The following conditions
were used for PCR: 95oC for 5 min (initial denaturation), denaturation at 95oC for 30 s,
annealing at 45oC for 30 s, and extension at 72oC for 30 s for 20, 25, or 30 cycles.

2.3.5 REAL-TIME PCR
RNA was isolated from PKR-/- MEFS transfected with either the CMV-TARLuciferase pGL3 Basic or CMV Luciferase pGL3 Basic plasmids and the indicated
combinations of Flag wt PKR/pcDNA 3.1-, Tat/pcDNA 3, and Flag PACT/pCMV2
expression constructs using RNAzol B as per the manufacturer’s instructions. DNAse
treatment was performed to remove plasmid DNA from isolated RNA using the DNAfreeTM DNAse Removal Kit (Ambion).
cDNA was synthesized as described above using random hexamer primers. Real
time PCR reactions were performed with serial dilutions of cDNA to ensure efficiency.
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Reactions were performed in triplicate in a total reaction of 20 μl and included 4 μl
cDNA, 250 nM firefly luciferase or β-actin primers, and SensiFAST™ SYBR® No-ROX Kit
(Bioline). All reactions were run on a BioRad CFX96 Real Time System C1000 Thermal
cycler machine with the following conditions: 95oC for 30 s, 95oC for 5 s, 53oC for 30 s
(steps were repeated for 35 cycles), 60oC for 5 s, and then 95oC for 5 s. We used the
BioRad CFX Manager software to generate standard curves to compare luciferase
expression in each sample. 2 separate RNA isolations from transfected PKR-/- MEFs were
used for analysis.

2.3.6 TRANSFECTIONS FOR LUCIFERASE REPORTER ASSAYS AND REAL-TIME PCR
ANALYSIS
All transfections were carried out in triplicate for each sample using indicated
cell types cultured in six-well plates using Effectene (Qiagen) transfection reagent and
500 ng of total DNA per well. One nanogram of pRL-null (Promega) plasmid was cotransfected for normalization of the transfection efficiencies. Cell extracts were
prepared at indicated time points and firefly and Renilla luciferase activities were
measured with Dual Luciferase Reporter Assay system (Promega).

2.3.7 PKR KINASE ACTIVITY ASSAY
PKR activity assays were performed using an anti-PKR monoclonal antibody
(71/10, R&D systems). HeLaM cells were maintained in DMEM containing 10% fetal
bovine serum. The cells were harvested when they were at 70% confluence. Cells were
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washed in ice-cold PBS and collected by centrifugation at 600 g for 5 min. Cell extracts
were prepared in lysis buffer [20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 50 mM KCl, 400mM
NaCl, 2 mM dithiothreitol (DTT), 1% Triton-X 100, 100 U/ml aprotinin, 0.2 mM
phenylmethylsulfonyl fluoride (PMSF) and 20% glycerol]. A 100 µg aliquot of total
protein was immunoprecipitated using the anti-PKR monoclonal antibody (71/10) in
high salt buffer [20 mM Tris-HCl pH 7.5, 50 mM KCl, 400 mM NaCl, 1mM EDTA, 1 mM
DTT, 1% Triton-X 100, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol] at 4oC for 30 min
on a rotating wheel. A 20 µl aliquot of Protein A-agarose beads was then added and
incubated for 1h. The Protein-A agarose beads were washed four times in 500 µl of
high-salt buffer and twice in activity buffer [20 mM Tris-HCl pH 7.5, 50 mM KCl, 2 mM
MgCl2, 2 mM MnCl2, 0.1 mM PMSF, 5% glycerol]. The PKR assay was performed with
PKR still attached to the beads in activity buffer containing 0.1 mM ATP and 1 µCi of
[γ32P] ATP at 30oC for 10 min. PKR was activated using synthesized TAR RNA (IDT DNA
Technologies) and the effect of PACT, Tat, ADAR1, and TRBP on TAR-activated PKR was
assayed by the subsequent addition of increasing amounts of pure recombinant PACT or
pure recombinant TRBP (4, 40, 400 pg and 4 ng) in the presence of recombinant Tat and
increasing amounts of recombinant ADAR1 (1.5, 15, and 150 ng). Labeled proteins were
analyzed by SDS-PAGE on a 12% gel followed by autoradiography.

2.3.8 CO-IMMUNOPRECIPITATION ASSAY
In vitro translated, 35S-labeled ADAR1 and flag epitope-tagged PACT and TRBP proteins
were synthesized using the TNT T7 coupled reticulocyte system from Promega. A 5 µl of

43

35S-labeled

proteins were mixed in indicated combinations and incubated with 20 µl of

anti-flag mAb–agarose (Sigma) in 200 µl of immunoprecipitation (IP) buffer [20 mM
Tris–HCl pH 7.5, 150 mM (or 300 mM) NaCl, 1 mM DTT, 100 U/ml aprotinin, 0.2 mM
PMSF, 20% glycerol and 1% Triton X-100] at RT for 30 min on a rotating wheel. The
beads were washed in 500 µl of IP buffer four times and the washed beads were then
boiled in Laemmli buffer [150 mM Tris–HCl pH 6.8, 5% SDS, 5% β-mercaptoethanol and
20% glycerol] for 2 min and eluted proteins were analyzed by SDS–PAGE on a 12% gel
followed by phosphorimager analysis for quantification.

2.3.9 YEAST TWO-HYBRID INTERACTION ASSAY
To compare the strength of TRBP-ADAR1 with PACT-ADAR1 interactions, ADAR1
was expressed as a GAL4 DNA-activation domain fusion protein from the pGADT7
vector, and TRBP and PACT were expressed as GAL4 DNA-binding domain fusion
proteins from the pGBKT7 vector. ADAR1 pGADT7 /TRBP pGBKT7 and ADAR1 pGADT7/
PACT pGBKT7 were co-transformed into AH109 yeast cells (Clontech), and the
transformed yeast cells were plated on double dropout SD (synthetic defined) minimal
medium lacking tryptophan and leucine. In order to check for the transformants’ ability
to grow on triple dropout media, transformed yeast cells were grown to an OD 600 of 2 in
liquid growth medium. A 500 μl aliquot of each culture was pelleted and resuspended in
an appropriate amount of distilled water to yield an OD600 of 10. Serial dilutions were
then made to yield OD600 values of 1, 0.1, and 0.01. A 10 μl aliquot of each dilution was
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then spotted onto triple dropout SD minimal media lacking histidine, tryptophan, and
leucine in. Plates were incubated at 30oC for 3 days.

2.3.10 QUANTIFICATION AND STATISTICS
Radioactive bands were scanned for the TRBP-ADAR1 and PACT-ADAR1 coimmunoprecipitation assays (Typhoon FLA7000) and were quantified using the GE Life
Sciences ImageQuant TL software. To determine the statistical significance of the results
of the co-immunoprecipitation assay and the β-galactosidase and luciferase assays, a
two-tailed Student’s t-test was performed, assuming equal variance. Each figure legend
indicates P-values as denoted by brackets and special characters. Note that our α-level
was P = 0.05.

2.4 RESULTS
2.4.1 PACT ENHANCES HIV-1 GENE EXPRESSION FROM A TAT-INDUCED INTEGRATED
LONG TERMINAL REPEAT
Our previous work indicated that PACT enhances expression from a HIV-1
promoter in transfected HeLa cells as well as viral replication in HIV-1 infected cells62,98.
Thus, in this context, PACT exhibited a proviral function similar to the PKR inhibitor
TRBP. To determine if PACT can enhance HIV-1 long terminal repeat (LTR)- driven gene
expression in the context of latently infected cells, we first compared the effects of TRBP
and PACT when HIV-1 LTR is integrated into the host chromosome. HeLa-MAGI-CCR5
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cells contain a stably integrated β-galactosidase coding region expressed under the
control of the HIV-1 LTR, whose transcription is dependent on HIV-1 Tat protein86,130–133.
We first verified that increasing amounts of Tat expression vector (blue bars)
resulted in a dose-dependent increase in β-galactosidase activity (Figure 2.1 A)
compared to the absence of Tat (black bar). Having confirmed that the cells are
responsive to Tat, we next evaluated the effect of PACT in comparison to TRBP. The
addition of PACT (green bars) or TRBP (red bars) expression constructs further
stimulated Tat-trans-activated HIV-1 LTR-driven β-galactosidase activity (Figure 2.1B).
Furthermore, the addition of increasing amounts of Tat expression plasmid (blue
bars) in the presence of a constant amount of PACT (green bars) or TRBP (red bars) led
to increased β-galactosidase activity in a dose-dependent manner (Figure 2.1C). In
contrast, in the absence of Tat, neither PACT (green bars) nor TRBP (red bars) had any
effect on HIV-1 LTR driven expression (Figure 2.1D). These results indicate that similar to
TRBP, PACT activates expression from HIV-1 LTR when integrated in the host
chromosome and that this effect is dependent on the presence of the viral Tat protein.

2.4.2 PACT DOES NOT AFFECT THE STEADY-STATE TRANSCRIPT LEVELS OF HIV-1 LTRDRIVEN GENES
To characterize PACT’s activating effect on HIV-1 LTR-driven gene expression as
either transcriptional or post-transcriptional, we performed semi-quantitative RT-PCR
analysis to assess changes in β-galactosidase mRNA levels in HeLa-MAGI-CCR5 cells
transfected with Tat and PACT or TRBP expression plasmids relative to β-actin mRNA
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levels (Figure 2.2). As expected, we observed that the expression of Tat increased βgalactosidase mRNA levels (lanes 4-6) when compared with empty vector transfected
HeLa-MAGI-CCR5 cells (lanes 1-3). As seen in lanes 7-9, there was no increase in βgalactosidase mRNA levels between HeLa-MAGI-CCR5 cells transfected with Tat alone
(lanes 4-6) and HeLa-MAGI-CCR5 cells transfected with Tat alone (lanes 4 -6) and HeLaMAGI-CCR5 cells transfected with Tat and TRBP (lanes 7-9) or Tat and PACT (lanes 1012).
These results show that the enhancing effect of PACT on β-galactosidase activity
in HeLa-MAGI-CCR5 cells was not a result of increased levels of β-galactosidase mRNA,
but resulted from a post-transcriptional mechanism. As all mRNAs produced from HIV-1
LTR promoter driven reporters contain a TAR structure in their 5’-UTRs, these results
indicate that PACT acts at a post-transcriptional level on TAR-containing mRNAs.

2.4.3 TAT AND PACT INHIBIT PKR ACTIVATION INDUCED BY TAR CONTAINING MRNAS
The translation of HIV-1 mRNAs is diminished by the TAR RNA secondary
structure in their 5’-UTRs and also by TAR- mediated PKR activation106,134,135. This effect
is partially compensated for by the cellular proteins TRBP and ADAR186,118,129,136,137 as
well as by the viral protein Tat126.
However, Tat also acts as a potent transcriptional trans-activator for HIV-1 LTRdriven genes, and in order to specifically study Tat’s post-transcriptional effects, we
used a system that is not affected at the transcriptional level by Tat. For this purpose,
we designed an expression construct CMV-TAR-LUC, in which the TAR RNA was placed
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directly upstream of the firefly luciferase open reading frame expressed from a CMV
promoter. A CMV-Luciferase expression construct (CMV-LUC) was designed as a control
without TAR. By producing TAR-containing transcripts from the CMV promoter which is
nonresponsive to Tat’s transcriptional transactivation, we could specifically assess Tat’s
post-transcriptional effects mediated by PKR activation.
To examine the activity of PACT and Tat on PKR-induced inhibition of translation,
PKR-/- MEFs were co-transfected with either CMV-TAR-LUC/pGL3 Basic or CMVLuciferase/pGL3 Basic along with PACT and Tat expression plasmids, and luciferase
activity was assessed. As seen in Figure 2.3A, co-transfection of PKR with CMV-TAR-LUC
(white bars) or CMV-LUC (black bars) reduced luciferase activity as previously reported
and in agreement with PKR’s effect on translation of plasmid-encoded
transcripts62,98,118,129. Furthermore, co-transfection of Tat with PKR rescued the PKRmediated reduction of luciferase activity only when TAR was present, indicating that Tat
can relieve the translational block imposed by PKR on TAR-containing mRNAs.
Surprisingly, PACT also counteracted TAR-induced PKR translational inhibition, whereas
it maintained PKR-mediated translational inhibition of plasmid-derived luciferase mRNA
in the absence of TAR, suggesting that the presence of TAR is required for both PACT
and Tat’s inhibitory effect on PKR. In addition, when expressed together, PACT and Tat
showed a further significant increase of luciferase expression with CMV-TAR-LUC, but
not with CMV-LUC.
These results indicate that PACT inhibits PKR activation on TAR-containing mRNAs, in
contrast with its well-characterized PKR-activating function61,121,122,138,139. Furthermore,
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this PKR-inhibitory activity of PACT can only occur in the presence of TAR- containing
mRNA transcripts (compare black bars with white bars) and is significantly enhanced in
the presence of Tat. These results suggest that during active production of HIV-1 viral
proteins, PACT acts in concert with Tat and TAR RNA to counteract PKR- mediated
inhibition of viral mRNA translation.
To ensure that the Tat-dependent, PACT-mediated inhibition of PKR was not a
result of changes in TAR-firefly luciferase mRNA or firefly luciferase mRNA transcript
levels, we performed qRT-PCR analysis to quantify firefly luciferase mRNA levels in total
RNA isolated from the PKR -/- MEFs transfected with the constructs indicated in Figure
2.3A. There were no significant differences in firefly luciferase mRNA levels in the
various samples (Figure 2.3B), demonstrating that PACT’s Tat-dependent effect on
luciferase expression is at translational level, most probably by counteracting PKR
activation.

2.4.4 TAT-TAR INTERACTION IS ESSENTIAL FOR PACT’S PKR INHIBITORY ACTIVITY
As we observed that Tat and PACT work synergistically to increase translation of
TAR containing mRNAs, we wanted to determine if Tat’s ability to bind to the TAR RNA
was essential for this function. To test this, we generated a CMV-TARm-LUC construct in
which the TARm RNA will not bind Tat but would still activate PKR59. PKR co-transfection
with this construct dramatically reduced the firefly luciferase activity (Figure 2.4A).
However, co-transfection of Tat or PACT had no effect on PKR-mediated inhibition of the
luciferase activity. These results show that Tat’s ability to interact with TAR-containing
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mRNAs is essential for the concerted PKR inhibitory effect of Tat and PACT on TARcontaining mRNAs.
To test that the PKR inhibitory effect was specific to Tat-PACT combination, we
performed the same transfection experiments with CMV-TAR-Luc and Rev, which is an
HIV-1 viral protein that binds to a different RNA structured element in viral mRNAs
known as the Rev response element211-213. Co-transfection of PKR reduced the luciferase
activity as shown in Figure 2.3A, but that of PACT or/and Rev had no effect on luciferase
activity (figure 2.4B). These results confirm that PACT’s PKR inhibitory activity on TARcontaining mRNAs specifically required Tat and its TAR RNA-binding activity is essential
for this function.

2.4.5 ADDITIONAL CELLULAR FACTORS ARE ESSENTIAL TO INHIBIT TAR RNA-MEDIATED
PKR ACTIVATION
Based on the above results, the combination of the TAR RNA. PACT, and Tat
seems to induce strong inhibition of PKR activation in cell culture. To determine if these
components are sufficient to provide complete PKR inactivation, we performed in vitro
kinase activity assays using PKR immunoprecipitated from HeLa cells to recapitulate the
mechanism in vitro. We first confirmed that PKR is activated robustly by TAR RNA similar
to the synthetic dsRNA polyI:C, with a bell-shaped activation curve with no activation at
low and high concentrations of TAR RNA (Figure 2.5A), as previously observed 214,94,215.
We then assessed PACT’s ability to inhibit or activate PKR activation caused by TAR RNA
in the absence (Figure 2.5B, lanes 3-6) or presence (Figure 2.5B, Lanes 7-10) of Tat. PACT
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remained a PKR activator in the presence of TAR-RNA (Figure 2.5B, lanes 3-6). In the
presence of Tat, a very modest inhibition of PKR activity with the highest amount of
PACT was observed (Figure 2.5B, Lane 10), indicating that PACT and Tat cannot
recapitulate PKR inhibition in vitro and that additional components present in the
mammalian cells are required for the observed inhibition of PKR activation on TARcontaining mRNAs.

2.4.6 THE RNA-EDITING PROTEIN ADAR1 IS ESSENTIAL FOR THE COMPLETE INHIBITION
OF TAR-ACTIVATED PKR BY TAT AND PACT
We previously reported that another double stranded RNA binding protein,
ADAR1, directly interacts with PKR and PACT during HIV-1 infection to form a PKRinhibitory complex98,119,129. Thus, we investigated if ADAR1 can inhibit TAR-activated PKR
when present together with Tat and PACT. Using an in vitro kinase assay, we observed
that ADAR1 can inhibit PKR activation efficiently in a dose-dependent manner (Figure
2.6, lanes 2-4).
Under these conditions, 150 ng of ADAR1 was required for complete inhibition of PKR
activity (lane 2), whereas 15 ng and 1.5 ng of ADAR1 showed partial (lane 3) and no
inhibition (lane 4), respectively. The addition of PACT did not improve or compromise
the PKR inhibitory function of ADAR1 (lanes 6-8). We then tested the effect of HIV-1 Tat
protein on PKR activity as our results in Figure 3 suggested that Tat is required for PKR
inhibition. When Tat was present, we observed a complete inhibition of PKR activity at
all concentrations of ADAR1 (lanes 9-12). Thus, the Tat protein seems to significantly
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enhance the PKR inhibitory actions of ADAR1; 100-fold less ADAR1 (lane 12, 1.5 ng
ADAR1) was sufficient to inhibit PKR activity in the presence of Tat, when compared
with the conditions where Tat was absent (lane 6, 150 ng ADAR1). Also, Tat when
present with ADAR1 does not enhance ADAR1’s PKR inhibitory actions when compared
with the inhibition observed with ADAR1 alone (lanes 14-16) when PACT is absent.
These results show that Tat, PACT, and ADAR1 act in concert to inhibit PKR and
suggest that an inhibitory complex formed with Tat, PACT, and ADAR1 is essential for
efficient PKR inhibition on TAR containing HIV-1 mRNAs. Tat by itself (data not shown)
or with PACT (Figure 2.5) does not inhibit PKR activity. To further confirm that Tat
enhances the PKR inhibitory activity of ADAR1 and PACT, we compared the effect of
lower concentrations of ADAR1 in the presence and absence of Tat. As seen in Figure
2.6B, in the absence of Tat, 1.5 ng of ADAR1 showed complete inhibition of PKR activity
(lane 2), and 150 and 15 pg ADAR1 showed no PKR inhibition (lanes 3 and 4,
respectively). In the presence of Tat, 1.5 ng ADAR1 showed complete inhibition (lane 6)
and 150 pg of ADAR1 showed partial inhibition of PKR activity (lane 7). These results
demonstrate that Tat enhances the PKR inhibitory actions of ADAR1 in the presence of
PACT, and that Tat may function to recruit PACT and ADAR1 to the complex after
binding to TAR in HIV-1 encoded transcripts.
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2.4.7 A COMPARISON OF PKR INHIBITORY ACTIVITY OF ADAR1 IN THE PRESENCE OF
PACT OR TRBP
As TRBP is known to inhibit PKR under various conditions including HIV infection,
we wished to compare the relative efficiency of PACT and TRBP to inhibit TAR RNAactivated PKR in the presence of Tat and ADAR1. As seen in Figure 2.7A, we observed
that similar to PACT, ADAR1 can inhibit PKR activation efficiently in a dose-dependent
manner in the presence of TRBP and Tat (lanes 4-6). Under these conditions, 150 ng
ADAR1 was required for a complete inhibition of PKR activity (lane 4). Unlike PACT
(which activates PKR in the absence of ADAR1), TRBP shows significant inhibition of PKR
even in the absence of ADAR1 (lane 3), and this inhibition is further enhanced by the
addition of ADAR1 (lanes 4-6).
Comparing the relative efficiency of TRBP and PACT to inhibit PKR, 100-fold less
ADAR1 is required in the presence of PACT (lanes 9-11) when compared to conditions
where TRBP was used (lanes 4-6) instead of PACT. Thus, PACT significantly enhances the
PKR inhibitory actions of ADAR1 when compared with TRBP (lanes 4-6 and 9-11). These
results show that Tat, PACT, and ADAR1 act in concert to inhibit PKR more efficiently
than Tat, TRBP, and ADAR1. One possible mechanism for PACT’s enhanced ability to
increase ADAR1’s effective inhibition of PKR could result from its higher affinity for
ADAR1. Therefore, we compared the relative strengths of PACT-ADAR1 and TRBPADAR1 interactions using a co-immunoprecipitation assay. We used an in vitro rabbit
reticulocyte translation system to generate 35S-methionine labeled ADAR1, PACT, and
TRBP proteins. As seen in Figure 2.7B, both PACT and TRBP can co-immunoprecipitate
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ADAR1 at 150 mM (lanes 4-6) and 300 mM (lanes 7-9) salt concentrations. However, at
both salt concentrations, PACT interacts significantly more efficiently with ADAR1 when
compared with TRBP (Figure 2.7C). At 150 mM salt concentration, PACT pulled down
12.3% of ADAR1, whereas TRBP could only pull down 3.2% of ADAR1. At 300 mM salt
concentration, PACT pulled down 7.3% of ADAR1 and TRBP pulled down only 1.1% of
ADAR1.
To compare the PACT-ADAR1 and TRBP-ADAR1 interactions further, we utilized a
yeast two-hybrid assay (Figure 2.7D). We have used this system extensively to
demonstrate that stress-induced phosphorylation of PACT results in changes in the
affinity of its interaction with TRBP and PKR60,67,140. Thus, the yeast two-hybrid system is
sensitive enough to detect changes in relative affinities between these proteins and
measures direct interaction between two proteins. As seen in Figure 2.7D, in
comparison with TRBP, PACT shows significantly stronger interaction with ADAR1. These
results further suggest that ADAR1 functions as a more efficient inhibitor of TAR RNAactivated PKR in the presence of PACT than in presence of TRBP, either because PACT
recruits ADAR1 with higher efficiency to TAR containing mRNAs or because ADAR1
forms a more stable PKR inhibitory complex with PACT. In HIV-infected cells, it is
possible that both TRBP and PACT serve redundant roles to form complexes with Tat,
ADAR1 and TAR RNA but PACT functions more efficiently to bring about PKR inhibition.
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2.5 DISCUSSION
In HIV-1 infected patients type I IFNs are produced by plasmacytoid dendritic
cells and exert both antiviral and immunomodulatory activities141. However, this IFN
response is insufficient to clear the virus from infected cells142,143. The inability of IFNs to
clear the virus is not due to a lack of cellular response to IFN since the ISGs are induced
in infected peripheral blood mononuclear cells (PBMCs) when in culture and show
inhibition of HIV-1 replication98. Thus, the absence of a robust IFN antiviral response in
patients is due to a block in the antiviral actions of ISGs. PKR is one of the ISGs whose
regulation has been studied extensively in the context of many viral infections including
HIV-1. PKR overexpression results in its activation that effectively restricts HIV-1
replication117,129,144–146. In addition, a knockdown of PKR using siRNAs or overexpression
of a trans-dominant negative PKR mutant results in increased HIV-1 replication in cell
culture137. In spite of this, the virus replicates efficiently in patient cells, suggesting that
PKR activity is heavily limited during the course of a natural infection129.
Our previous work showed that PKR activation takes place only transiently after
HIV-1 infection of PBMCs or of lymphocytic cell lines with either X4 or R5 HIV-1 strains,
suggesting that PKR activation is rapidly inhibited by the presence of HIV-1, which
removes a barrier to replication129. During the course of HIV-1 infection, PKR is activated
by the TAR RNA and inhibited by TRBP, ADAR1 and the viral Tat proteins. Of these
inhibitors, the HIV-1 protein Tat inhibits PKR by acting as a substrate competitor81,82,126
whereas TRBP and ADAR1 inhibit PKR activity by direct interaction. TRBP also sequesters
the activator dsRNA and PACT molecules by a direct interaction with them95,117. ADAR1
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was previously identified as an important contributor for effective PKR inhibition and
has emerged as exhibiting both antiviral and proviral functions78,109. ADAR1 catalyzes
the deamination of adenosine in RNAs with dsRNA regions, thereby causing a
destabilization of RNA duplexes and genetic recoding123. Thus, ADAR1 functions as a
suppressor of dsRNA-mediated antiviral responses, which include activation of PKR and
IFN regulatory factor IRF3, the transcription factor for IFN genes78. The p150 isoform of
ADAR1 is an ISG, present both in the cytoplasm and nucleus, as while the p110 isoform
is constitutively expressed and is predominantly present in the nucleus147.
The results presented here demonstrate that TAR-mediated PKR activation is
also suppressed by a complex of PACT, ADAR1, and the viral protein Tat. Thus, in
addition to its well-established functions in the nucleus and in transcription of HIV-1
proviral genome, Tat plays an important function in enhancing HIV-1 mRNA translation
in the cytoplasm. Furthermore, in this complex, PACT is unable to activate PKR and that
ADAR1 and Tat are essential for repressing PACT’s canonical PKR activating role. Neither
Rev nor a mutated TAR can inhibit PKR activation, thus suggesting that TAR RNA serves
as a scaffold to recruit and stabilize many RNA-binding proteins, and PACT’s PKRactivating ability is inactivated by the recruitment of ADAR1 to this complex. It is
possible that Tat binds to TAR first to recruit PACT, which in turn is able to efficiently
bring ADAR1 to the complex. Our previous data established that PACT and ADAR1
interact directly98 and our current results show that Tat has an essential function in this
complex. Overall, our results suggest that during HIV-1 infection, cytoplasmic Tat may
bind to the TAR RNA to simultaneously recruit PACT and ADAR1 to serve a PKR
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inhibitory role. This complex serves a crucial role in enhancing translation of viral
proteins needed for efficient viral replication as PKR is known to bind to the stem region
of TAR RNA148.
In addition to its classical transcriptional trans-activation role in the nucleus,
Tat’s cytoplasmic functions during HIV-1 replication have been reported before in other
studies149,150. Tat protein counteracts the effect of TAR to stimulate translation of the
viral mRNAs by enhancing the activity of RNA helicase DDX3151–154. Tat also showed a
stimulatory effect on global protein synthesis by competing with eIF2α for
phosphorylation by PKR or by inhibiting PKR activity, independently of the presence of
TAR [reviewed in reference119]. Our work introduces one more regulatory layer for Tat’s
central role in HIV-1 replication. As represented in Figure 2.8, our results establish that
for efficient translation of TAR-containing mRNAs, the interaction between TAR and Tat
is essential to promote the formation of a PKR inhibitory complex that contains PACT
and ADAR1. Using a mutated TAR region that does not bind Tat but can activate PKR
efficiently, we demonstrate that PKR-mediated translational downregulation was not
overcome in the absence of TAR-Tat interaction (Figure 2.4).
As a part of this multiprotein complex, PACT is unable to activate PKR and ADAR1
strongly represses PKR activity (Figure 2.6). ADAR1 has been shown to inhibit PKR
activity and reduce eIF2α phosphorylation efficiently to play a proviral role during the
replication of several DNA and RNA viruses78,105. Overexpression of either the full-length
ADAR1 p150 protein or the region with the RNA- and Z-DNA binding domains alone
inhibited PKR autophosphorylation and eIF2α phosphorylation129,155. A stable
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knockdown of ADAR1 expression causes enhanced PKR autophosphorylation and eIF2α
phosphorylation following infection with measles virus or vesicular stomatitis virus156,157.
In ADAR1 containing cells, PKR autophosphorylation is suppressed following a viral
infection, but in ADAR1-deficient cells it is enhanced because of the lack of editingmediated destabilization of dsRNA, lack of sequestration of dsRNA by ADAR1 and also
due to a lack of formation of inactive heterodimeric ADAR1:PKR complexes78.
Furthermore, a depletion of ADAR1 by RNAi in human cells or by genetic
knockout in mouse MEFs leads to enhanced apoptosis and cytotoxicity following
infection with RNA viruses from the Paramyxoviridae and the Rhabdoviridae families as
well as the polyoma DNA virus156–159. Using an overexpression screening strategy in
which more than 380 human ISGs were tested for their antiviral activity against many
medically important viruses, ADAR1 emerged as the most potent proviral ISG, which
enhanced the replication of HIV-1, West Nile virus, Chikungunya virus, Venezuelan
equine encephalitis virus, and yellow fever virus160. In case of HIV-1 infection, our results
demonstrate that ADAR1 is important to suppress PKR activation by TAR RNA to allow
for efficient synthesis of viral proteins as only Tat, PACT, and TAR RNA cannot block PKR
activation efficiently in the absence of ADAR1 (Fig. 2.6).
Several viruses have been shown to inactivate PACT function in the infected cells
as PACT is involved both in activating PKR to suppress viral protein synthesis and in IFN
production via RIG-I like receptors (RLRs)161. Middle East Respiratory Syndrome
Coronavirus 4a protein162, Herpes Simplex Virus US 11 protein163,164, Ebola virus VP35
protein165, Influenza virus NS1 protein166, and orf virus ov20.2 protein167 have been
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shown to inactivate PACT. Overall, our results show that the suppression of PACT
activity to effectively inactivate PKR in HIV-1 producing cells is the result of the
combined activity of the recruited ADAR1 that mediates PKR kinase inhibition, and Tat
most likely stabilizes the complex formed by PKR, PACT and ADAR1. Any effect that Tat
may have on PACT’s function in the RLR mediated IFN production remains to be
explored in future.
The results presented here shed light on how efficient translation of TARcontaining HIV-1 encoded RNAs takes place by suppressing PKR activation. The present
work also presents us with new paradigms for testing possible ways to suppress HIV-1
viral protein synthesis. For example, if the formation of the inhibitory complex could be
prevented by use of peptides that may block interaction between various components
of this complex, we may be able to keep PKR activated in virally infected cells to prevent
or at least partially block viral replication.
.

59

Figure 2.1: PACT activates Tat-enhanced HIV-1 gene expression from an integrated LTR
(A). Requirement and dose response curve for Tat for HIV-1 LTR driven expression.
HeLa-MAGI-CCR5 cells were transfected with 0 (black bar) or increasing amounts of
Tat/pcDNA 3 (blue bars) as indicated.
β-Galactosidase activity was assayed 24 hours after transfection. Error bars indicate
standard deviation calculated from three independent experiments. The P-value
(0.0000038) calculated using statistical analyses indicated significant difference between
the RLU values indicated by the bracket marked as ‘*’.
(B and C) PACT and TRBP both enhance HIV-1 LTR driven expression. (B) HeLa-MAGICCR5 cells were transfected with 0 (black bar), or 1ng Tat/pcDNA 3 (Blue bar) with
increasing amounts of Flag TRBP/pcDNA 3.1- (Red bars) or Flag PACT/pCMV2 (Green
bars) as indicated. The P-values (0.0045 and 0.0044) calculated using statistical analyses
indicated significant difference between the RLU values indicated by the brackets
marked as ‘*’ and ‘**’ respectively. (C) HeLa-MAGI-CCR5 cells were transfected with 0
ng, (black bar), increasing amounts of Tat/pcDNA 3 (blue bars) and with 10ng of Flag
TRBP/pcDNA 3.1- (red bars) or with Flag PACT/pCMV2 (green bars). β-Galactosidase
activity was assayed 24 hours post-transfection. Error bars indicate standard deviation
calculated from three independent experiments. The P-values (0.0011 and 0.0004)
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Figure 2.1 (continued) calculated using statistical analyses indicated significant
difference between the RLU values indicated by the brackets marked as ‘*’ and ‘**’
respectively.
D. PACT and TRBP have no effect on HIV-1 LTR driven expression in the absence of Tat.
HeLa-MAGI-CCR5 cells were transfected with 0 (black bar), or increasing amounts of Flag
TRBP/pcDNA 3.1- (red bars), or Flag PACT/pCMV2 (green bars). β-Galactosidase activity
was assayed 24 hours post-transfection. All transfections were compensated to the
same amount of DNA with pcDNA 3.1. Error bars indicate standard deviation calculated
from three independent experiments. The P-values (0.3863 and 0.9124) calculated using
statistical analyses indicated no significant difference between the RLU values indicated
by the brackets marked as ‘#’ and ‘##’ respectively.
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Figure 2.2: PACT does not increase the steady –state mRNA levels of HIV-1 LTR-driven
β-galactosidase.
RNA was isolated from HeLa-MAGI-CCR5 cells transfected with pcDNA 3.1- only (-Tat,
lanes 1-3), Tat/pcDNA 3 (+ Tat alone, lanes 4-6), Tat/pcDNA 3 and Flag TRBP/pcDNA 3.1(Tat + TRBP, lanes 7-9), or Tat/pcDNA 3 and Flag PACT/pCMV2 (Tat + PACT, lanes 10-12).
The RNA preparation was treated extensively with DNase to digest any DNA
contamination. β-Galactosidase mRNA expression levels were analyzed by semiquantitative RT-PCR at the indicated number of reaction cycles. β-actin mRNA levels
were also analyzed as a normalization control for each cycle number. No PCR products
were obtained in the absence of reverse transcriptase.
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Figure 2.3: PACT inhibits PKR activation induced by TAR-containing mRNAs.
A. Tat enhances PACT mediated PKR inhibition on TAR containing mRNAs. PKR -/- MEFs were co-transfected with CMV-TARLuciferase or CMV-Luciferase (in pGL3 Basic plasmid backbone), and indicated combinations of Tat/pcDNA3, Flag PKR/pcDNA 3.1 -,
and Flag PACT/pCMV2. Firefly luciferase activity was assayed 24 h post-transfection and the error bars represent the standard
deviation from three experiments. The P-values (0.0018 and 0.4601) calculated using statistical analyses indicated significant and
non-significant differences between the RLU values indicated by the brackets marked as ‘*’ and ‘#’ respectively.

Figure 2.3 (continued) B. qRT-PCR analysis. qRT-PCR analysis was performed to analyze luciferase mRNA expression levels in
samples from PKR-/- MEFs transfected as described in A. Data represents the average from six replicate experiments from two
different RNA isolations. All results are normalized to β-actin.

64

65

Figure 2.4: Tat serves a specific function in mediating inhibition of PKR.
A. Tat’s binding to the TAR is essential for PACT mediated PKR inhibition. PKR-/- MEFs were co-transfected with CMV mutant-TAR
Luciferase (in pGL3-Basic plasmid backbone:EV) in which the mutant TAR element does not bind to Tat and the indicated
combinations of Tat/pcDNA 3, Flag PKR/pcDNA 3.1-, and Flag PACT/pCMV2. Firefly Luciferase activity was assayed 24 h posttransfection and the error bars represent the standard deviation from three experiments. The P-value (0.5852) calculated using
statistical analyses indicated a non-significant difference between the RLU values indicated by the bracket marked as ‘#’.
B. Rev, another HIV-1 encoded RNA-binding protein cannot substitute for Tat’s function. PKR-/- MEFs were co-transfected with the
CMV TAR Luciferase expression construct and the indicated combinations of Rev/pcDNA 3, Flag PKR/pcDNA 3.1-, and Flag
PACT/pCMV2. Luciferase activity was assayed 24 h after transfection and the error bars represent the standard deviation from three

Figure 2.4 (continued) experiments. The P-value (0.5852) calculated using statistical analyses indicates no significant difference
between the RLU values indicated by the bracket marked as ‘##’.
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Figure 2.5: PACT and Tat are insufficient to inhibit TAR RNA dependent PKR activation.
A. TAR RNA activates PKR: PKR immunoprecipitated from HeLaM cell extracts was
activated by the addition of increasing amounts of TAR RNA as indicated (Lanes 3-8) or
poly I:poly C (Lane 2, ds). Lane 1 indicates activity in the absence of any activator. The
phosphorylated proteins were analyzed by SDS-PAGE and phosphorimager analysis.
B. Efficient inhibition of PKR requires components in addition to PACT and Tat. PKR
immunoprecipitated from HeLaM cell extracts was activated with 67 pg TAR RNA [Lanes
2-10]. Increasing amounts of pure recombinant PACT [Lanes 3-6 and Lanes 7-10] were
added in absence of Tat [Lanes 3-6] or in combination with 4 ng of pure recombinant Tat
[Lanes 7-10]. PACT amounts are as follows: 4 pg [Lanes 3 and 7], 40 pg [Lanes 4 and 8],
400 pg [Lanes 5 and 9], and 4 ng [Lanes 6 and 10]. Lane 1 (C) shows the PKR activity
without any added activator. The phosphorylated proteins were analyzed by SDS-PAGE
and phosphorimager analysis.
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Figure 2.6. ADAR1 is essential for an efficient inhibition of PKR.
(A) ADAR1, PACT, and Tat inhibit PKR efficiently. PKR immunoprecipitated from HeLaM cell extracts was activated with 67 pg of
TAR RNA and varying amounts (150, 15, and 1.5 ng) of ADAR1 (Lanes 2-4, lanes 6-8, 10-12, and 14-16) were added as indicated to
assess the inhibition of PKR. Lanes 2-4: PKR activity in presence of varying amounts of ADAR1; Lanes 6-8: PKR activity in the presence
of 4 ng of PACT and varying amounts of ADAR1, lanes 10-12: PKR activity in the presence of 4 ng of PACT, 4 ng of Tat, and varying
amounts of ADAR1; lanes 14-16: PKR activity in the presence of 4 ng of Tat and varying amounts of ADAR1. The phosphorylated
proteins were analyzed by SDS-PAGE and phosphorimager analysis.

Figure 2.6 (continued) B. ADAR1 and PACT inhibit PKR more efficiently in the presence of Tat. PKR immunoprecipitated from
HeLaM cell extracts was activated with 67 pg of TAR RNA and varying amounts (1.5 ng, 150 pg, and 15 pg) of ADAR1 (Lanes 2-4 and
lanes 6-8) were added as indicated to assess the inhibition of PKR. Lanes 2-4: PKR activity in presence of varying amounts of ADAR1
and 4 ng of PACT; Lanes 6-8: PKR activity in the presence of varying amounts of ADAR1, 4 ng of PACT, and 4 ng of Tat. The
phosphorylated proteins were analyzed by SDS-PAGE and phosphorimager analysis.
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Figure 2.7. Comparison of TRBP and PACT’s PKR inhibitory activity on TAR RNA.
(A) PACT is more efficient compared with TRBP in forming a PKR inhibitory complex.
PKR immunoprecipitated from HeLaM cell extracts was activated with 67 pg of TAR RNA.
Either 4 ng of PACT (lane 2) or TRBP (lane 8) or 4 ng of TRBP (lanes 4-6) or PACT (lanes 911), 4 ng Tat, and varying amounts (150, 15, and 1.5 ng) of ADAR1 (Lanes 4-6 and 9-11)
were added as indicated to assess the inhibition of PKR. Lanes 4-6 represent PKR activity
in the presence of 4 ng of TRBP. Lanes 9-11 represent PKR activity in the presence of 4
ng of PACT. Lane 1 (C) shows the PKR activity without any added activator. The
phosphorylated proteins were analyzed by SDS-PAGE and phosphorimager analysis.
(B) PACT interacts with ADAR1 with higher affinity when compared with TRBP. A 5 µl
aliquot of in vitro translated, 35S-labeled Flag-tagged PACT and TRBP proteins was mixed
with 5 µl of in vitro translated, 35S-labeled ADAR1. Flag-PACT proteins were
immunoprecipitated using anti-Flag mAb-agarose, and ADAR1 co-immunoprecipitation
was analyzed by SDS-PAGE. Total: input (20% of the IP samples); IP:
immunoprecipitates. The bands seen at lower positions that the TRBP band in lanes 3, 6,
and 9 are truncated TRBP proteins produced by translation initiation at internal
methionines in the reticulocyte lysate system.
(C) Quantification of data in B. The radioactivity present in the bands was measured by
phosphorimager analysis and the % co-IP was calculated as follows: (radioactivity
present in the co-immunoprecipitated ADAR1 band/the radioactivity present in the
ADAR1 band in the total lane) X 100. This value was normalized to the amount of
radioactivity present in the PACT or TRBP bands in IP lanes to correct for differences in
translation/immunoprecipitation. Error bars: standard deviation from three
independent experiments. The P-values (0.000029 and 0.000051) calculated using
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Figure 2.7 (continued) statistical analyses indicate significant difference between % coIP of ADAR1 with PACT (white bars) and TRBP (black bars) at 150 mM (*) and 300 mM
(**) salt concentrations respectively.
(D) Yeast two-hybrid assay to compare TRBP-ADAR1 and PACT-ADAR1 interactions.
TRBP or PACT in pGBKT7 and ADAR1 in PGADT7 or empty pGADT7 plasmids were cotransformed into AH109 yeast cells and selected on SD double dropout media lacking
tryptophan, and leucine. Aliquots (10 µl) of serial dilutions (OD600 = 10, 1.0, 0.1, 0.01)
were spotted for each transformant on triple dropout SD medium plate that lacks
tryptophan, leucine and histidine. Plates were incubated for three days at 30 oC.
Transformation of PACT or TRBP constructs in pGBKT7 and empty vector pGADT7 served
as negative controls.
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Figure 2.8: Schematic model. When TAR RNA present at the 5’ end of HIV-1 encoded
transcripts binds PKR, activated PKR blocks translation of TAR-containing HIV-1 mRNAs.
Efficient translation of HIV-1 viral proteins occurs by recruiting viral protein Tat and host
factors PACT and ADAR1, to efficiently block PKR activation, thereby allowing synthesis
of viral proteins. In this complex, the PKR activating role of PACT is suppressed by the
presence of ADAR1.
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CHAPTER 3

STRESS-INDUCED TRBP PHOSPHORYLATION ENHANCES ITS INTERACTION
WITH PKR TO REGULATE CELLULAR SURVIVAL3

3

Chukwurah, E. and Patel R.C. Submitted to Scientific Reports, 2017
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3.1 ABSTRACT
Transactivation response element RNA-binding protein (TRBP or TARBP2) initially
identified to play an important role in human immunodeficiency virus (HIV) replication
has also emerged as a regulator of microRNA biogenesis. In addition, TRBP functions in
signaling pathways by negatively regulating the interferon-induced double-stranded
RNA (dsRNA)-activated protein kinase (PKR) during viral infections and cell stress.
During cellular stress, PKR is activated and phosphorylates the α subunit of the
eukaryotic translation factor eIF2, leading to the cessation of general protein synthesis.
TRBP inhibits PKR activity by direct interaction as well as by binding to PKR’s two known
activators, dsRNA and PACT, thus preventing their interaction with PKR.
In this study, we demonstrate for the first time that TRBP is phosphorylated in response
to oxidative stress and upon phosphorylation, inhibits PKR more efficiently promoting
cell survival. These results establish that PKR regulation through stress-induced TRBP
phosphorylation is an important mechanism ensuring cellular recovery and preventing
apoptosis due to sustained PKR activation.

3.2 INTRODUCTION
The double-stranded RNA (dsRNA)-activated protein kinase (PKR) is an interferon
(IFN)-induced serine/threonine protein kinase expressed ubiquitously in mammalian
cells108,121,168. Although IFNs induce expression of PKR at a transcriptional level, PKR’s
kinase activity stays latent until it binds to one of its activators leading to its
autophosphorylation and catalytic activation169. The best-characterized cellular
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substrate of PKR is the translation initiation factor, eIF2α, the phosphorylation of which
on serine 51 (S51) results in an inhibition of protein synthesis115,170. An immediate
response of cells exposed to various forms of stress is a general inhibition of protein
synthesis, which is mainly caused by the increased S51 phosphorylation of eIF2α 2. The
eIF2α phosphorylation thus serves an important function to block the general protein
synthesis and allow cells to either recover from stress or undergo apoptosis when the
damage is beyond repair1. PKR plays an important role in regulating apoptosis after
exposure to several diverse stress signals that include viral pathogens, oxidative stress,
endoplasmic reticulum (ER) stress, and growth factor or serum deprivation34,171.
During viral infections, the double-stranded dsRNA, which is a replication
intermediate for several viruses172, activates PKR by a direct interaction. The dsRNA
binds to PKR via the two dsRNA-binding motifs (dsRBMs) present at the N terminus45,173–
175,

changing the conformation of PKR to expose the ATP-binding site44,50 and

consequent autophosphorylation48. The two dsRBMs also mediate dsRNA-independent
protein-protein interactions with other proteins that carry similar domains176,177. Among
these are proteins inhibitory for PKR activity such as TAR RNA-binding protein (TRBP)95,
and also a PKR activating protein (PACT)58,60. PKR activation in response to stress signals
is tightly regulated by PACT and TRBP, both acting to regulate its catalytic activity by a
direct interaction with PKR as well as with each other67,98. As the dsRBMs in PKR, PACT,
and TRBP mediate protein-protein interactions178, these three proteins form both
heterodimers as well as homodimers and the stress-dependent phosphorylation of PACT
changes the relative strengths of PKR-PACT, PACT-TRBP, and PACT-PACT interactions to
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bring about timely and transient PKR activation with precise control67,68. This regulates
the general kinetics as well as level of eIF2 phosphorylation thereby influencing the
cellular response to stress either to recovery and survival or elimination by apoptosis179.
TRBP has three dsRBMs; the first two are true dsRBMs and interact with dsRNA,
while the third carboxy-terminal dsRBM mediates TRBP’s interactions with other
proteins such as Dicer, and Merlin91,123,178. TRBP inhibits PKR by interacting with dsRNA
and sequestering it away from PKR as well as by forming PKR-TRBP heterodimers95,120. In
the absence of viral infections and stress signals, TRBP forms heterodimers with both
PKR and PACT, preventing their association and PACT-mediated PKR activation97,180.
Importantly, the stress-induced serine 287 phosphorylation of PACT decreases its
interaction with the PKR inhibitory protein TRBP thereby further aiding in rapid PKR
activation following exposure to stress signals67,180. In contrast, not much is known
about how similar post-translational modifications may affect TRBP’s interaction with
PKR and consequently, its ability to inhibit PKR during cellular stress. Previous reports
indicate that TRBP is phosphorylated by the two MAPKs; ERK 1/2 and JNK, with specific
effects on RISC component stability and PKR activation by endogenous Alu transcripts
during mitosis respectively92,181.
In this study, we used various biochemical assays to determine if TRBP
undergoes stress-induced phosphorylation, and if this affects TRBP’s ability to inhibit
PKR during oxidative stress. Our findings implicate MAPKs (ERK1/2 and JNK) in oxidative
stress-induced TRBP phosphorylation, and show that TRBP phosphorylation significantly
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enhances TRBP’s ability to interact with and inhibit PKR during oxidative stress to
regulate apoptosis.

3.3 MATERIALS AND METHODS
3.3.1 REAGENTS, CELL LINES AND ANTIBODIES.
HeLaM and HeLa Tet off cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10% fetal bovine serum and penicillin/streptomycin. Transfections
were performed with Effectene Transfection Reagent (Qiagen) according to the
manufacturer’s protocol.
Tetracycline inducible cell lines stably expressing Flag TRBP were generated by
transfection of HeLa Tet off cells with 500 ng of Flag TRBP/pTRE2pur expression plasmid.
Selection of puromycin-resistant colonies was carried out 24 hours after transfection by
the addition of 700 ng/ml puromycin. Another cell line was also established using the
pTRE2 puro plasmid as a control. Doxycycline inducibility was quantified in Flag
TRBP/pTRE2pur cell clones after removal of doxycycline by western blot analysis.
Sodium arsenite, phosphatase inhibitor cocktail (Phosphatase Inhibitor Cocktail 2
– P5726), and the JNK inhibitor (SP600125, Catalog number S5567) were purchased
from Sigma Aldrich. MEK1/MEK2 inhibitor (PD0325901) was purchased from
Calbiochem (444968).
Antibodies used are as follows: mouse monoclonal anti-FLAG M2 HRP (SigmaAldrich A8592), mouse monoclonal anti-c-Myc HRP 9E10 (Santa Cruz Biotechnology SC40), mouse monoclonal anti-polyhistidine clone His-1 HRP (Sigma-Aldrich A7058), mouse
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monoclonal anti-PKR (R&D systems MAB1980), rabbit polyclonal anti-phospho PKR Thr
451 (Cell Signaling Technology 3075), rabbit monoclonal anti-Phospho-p44/42 MAPK
(Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® (Cell Signaling Technology 4370), rabbit
monoclonal anti-p44/42 MAPK (Erk1/2) (137F5) (Cell Signaling Technology 4695), rabbit
polyclonal anti-PARP (Cell Signaling Technology 9542), mouse monoclonal anti-β-Actin
HRP (Sigma-Aldrich A3854), mouse monoclonal anti-GAPDH HRP (Sigma-Aldrich G9295),
goat anti-mouse IgG HRP (Sigma-Aldrich A3682), and goat anti-rabbit IgG HRP (BioRad
170-6515).

3.3.2 PLASMIDS
The Flag TRBP/BSIIKS+, TRBP/pGBKT7, K296R PKR/pGAD424 and PKR /pYES2 expression
plasmids were prepared as previously56,67,182. Full length TRBP1 ORF with an N-terminal
Flag tag from Flag TRBP/BSIIKS+ was inserted into the NotI and EcoRV restriction sites of
the tetracycline-responsive vector, pTRE2pur (Clontech) to generate Flag TRBP/
pTRE2pur. The phospho-defective (TRBP AAAA) and phospho-mimic (TRBP DDDD) point
mutants were generated at S121, S131, S262, and S265 by substituting each serine with
alanine or aspartic acid using the following primers:
TRBP sense:
5’-GCTCTAGACATATGGAAATGCTGGCCGCCAACC-3’
S121D antisense:
5’- GTTCCATGGCGGGGTCCCTGGTTAGGACTACAGATGGAACTGGGG-3’
S121A antisense:
5’- GTTCCATGGCGGGGGCCCTGGTTAGGACTACAGATGGAACTGGGG-3’
S131D sense:
5’-CGCCATGGAACTGCAGCCCCCTGTCGACCCTCAGC-3’
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S262D S265D antisense:
5’CGGAGCTCACTGAGGACACGGCAGCAGGCAGGGCCCAGGGCACCCAGGTCGCCCAGGTCGC
AACTGC-3’
S131A sense:
5’- CGCCATGGAACTGCAGCCCCCTGTCGCCCCTCAGC -3’
S262A S265A antisense:
5’CGGAGCTCACTGAGGACACGGCAGCAGGCAGGGCCCAGGGCACCCAGGGCGCCCAGGGCG
CAACTGC-3’

The PCR products were sub-cloned into the pGEMT-Easy vector (Promega) and
each sequence was verified. Full length AAAA TRBP and DDDD TRBP point mutants were
generated in the pGBKT7 yeast expression vector (Clontech) by three-piece ligation of
NdeI-NcoI restriction fragment from S121A or S121D/pGEMT-Easy, NcoI-SacI restriction
fragment from S131D S262D S265D or S131A S262A S265A/pGEMT Easy and NdeI-SacI
cut TRBP/pGBKT7. Each point mutant was subsequently introduced into the pGADT7
yeast expression vector (Clontech) by insertion of the NdeI-BamHI restriction fragment
from AAAA TRBP or DDDD TRBP/pGBKT7 into the NdeI-BamHI restriction sites in
pGADT7.
Flag-tagged full length AAAA and DDDD TRBP point mutants in pcDNA 3.1 (Invitrogen) were generated by first introducing the NdeI-BamHI restriction piece from
AAAA TRBP/pGBKT7 or DDDD TRBP/pGBKT7 into NdeI-BamHI cut Flag/TRBP BSIIKS+, and
then inserting the XbaI-BamHI restriction fragment from Flag/AAAA TRBP BSIIKS+ or
Flag/DDDD TRBP BSIIKS+ into the XbaI-BamHI sites in pcDNA 3.1-. Myc-tagged full length
AAAA and DDDD TRBP point mutants were generated by introducing HincII-BamHI
restriction fragments from AAAA TRBP/pGBKT7 and DDDD TRBP/pGBKT7 into the
EcoRV-BamHI restriction sites in pcDNA 3.1-.
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3.3.3 DNA FRAGMENTATION ANALYSIS
5 X 106 Flag TRBP/pTRE2pur and pTRE2pur HeLa tet off cells described in
“Reagents, Cell Lines and Antibodies” were treated with 10 μM sodium arsenite for the
indicated time points. Cells were collected and washed with ice cold 1X PBS, and lysed in
100 μl of lysis buffer [10mM Tris-HCl pH 7.5, 10mM EDTA, and 0.5% Triton-X 100] for 5
minutes on ice. Lysates were centrifuged at 13200 rpm for 5 minutes, and were
incubated with 100 μg Proteinase K at 37oC for 2 hours. 5 μl of 6M NaCl and 110 μl of
isopropanol were subsequently added to the lysates which were then incubated at 20oC
overnight. The precipitated DNA was then collected by centrifugation at 14,000 rpm for
5 minutes. After the isopropanol was removed from each sample, the DNA was
dissolved in 20 μl TE Buffer [10 mM Tris-HCl pH 7.5, 10 mM EDTA]. The DNA was
incubated with 20 μg/ml RNase A at 37oC for 1 hour before analysis on a 1.5% agarose
gel.

3.3.4 WESTERN BLOT ANALYSIS
Cells were treated with sodium arsenite alone or in combination with 10 μM
MEK1/MEK2 inhibitor PD0325901 (Calbiochem) or 10 μM JNK inhibitor SP600125 and
harvested at indicated time points. Cells were washed twice with ice cold 1X PBS.
Harvested cells were lysed in western lysis buffer [2% Triton X-100, 20 mM Tris–HCl pH
7.5, 100 mM KCl, 200 mM NaCl, 4 mM MgCl2, 40% Glycerol, and phosphatase inhibitor
cocktail 2 (Sigma) at 1:100 dilution] for 5 minutes on ice. Lysates were centrifuged at
13,200 rpm for 2 minutes. Protein concentration in the supernatant was quantified
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using Bradford reagent. Western blot was performed with the indicated antibodies and
western blot images were analyzed using the Typhoon FLA 7000 and ImageQuant LAS
4000 (GE Health).

3.3.5 TRBP-PKR PULL-DOWN ASSAY
Flag TRBP/pTRE2pur HeLa Tet off cells grown to 50% confluency in 100-mm
dishes were treated with 25 μM sodium arsenite for the indicated time points. Cell
extracts were prepared in 100 μl co-immunoprecipitation buffer [20 mM Tris-HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1% Triton-X 100, 2% Glycerol, and phosphatase
inhibitor cocktail 2 (Sigma) at 1:100 dilution]. 25 μg of cell extract was bound to 500 μg
of recombinant, hexahistidine-tagged PKR (His-PKR) protein immobilized on Ni2+-agarose
resin (Novagen) in 100 μl co-immunoprecipitation buffer at 4oC for 1 hour.
The beads were washed in 500 μl of co-immunoprecipitation buffer three times and
bound Flag-TRBP was analyzed by western blot analysis using anti-Flag antibody. Blot
was then stripped and re-probed with anti-His antibody to ascertain equal His-PKR pull
down. 25 μg aliquots of whole cell-lysate were analyzed by western blot analysis with
anti-Flag and anti-GAPDH antibodies to ensure that equal amounts of cell lysate were
used for immunoprecipitation.

3.3.6 TRBP-TRBP CO-IMMUNOPRECIPITATION ASSAY
HeLa cells were co-transfected in 6-well culture dishes with 250 ng each of (i)
myc TRBP DDDD/ pcDNA 3.1- and Flag TRBP DDDD/ pcDNA 3.1-, (ii) myc TRBP DDDD/
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pcDNA 3.1- and pcDNA 3.1- (iii) myc TRBP AAAA/ pcDNA 3.1- and Flag TRBP AAAA/
pcDNA 3.1-, (iv) myc TRBP AAAA/ pcDNA 3.1- and pcDNA 3.1- using the Effectene reagent
(Qiagen). 24 hours after transfection, cell extracts were prepared in co-IP buffer (150
mM NaCl, 30 mM Tris-HCl pH 7.5, 1 mM MgCl2, 10% Glycerol, 0.4% Igepal). Flag TRBP
AAAA and Flag TRBP DDDD were immunoprecipitated with anti-Flag mab-agarose
(Sigma) in co- IP buffer. The agarose beads were washed 5 times in co-IP buffer. The
bound proteins were then analyzed by western blot analysis with the anti-c-myc (Santa
Cruz Biotechnology) and anti-Flag (Sigma) antibodies.

3.3.7 YEAST GROWTH INHIBITION ASSAY
Wild-type and TRBP phospho-mimic and phospho-defective point mutants were
subcloned into the pYES3CT yeast expression plasmid (Invitrogen). Wild-type PKR was
subcloned into the pYES2 yeast expression vector (Invitrogen) as previously described
for galactose inducible PKR expression. The constructs were introduced into InvSc1
yeast cells (Invitrogen) using the Clontech Yeast Transformation Kit. Transformed yeast
cells were grown to an OD600 of 2 in YPD media (yeast extract, peptone, and dextrose).
500 μl of each culture was pelleted and resuspended in an appropriate amount of
distilled water to yield an OD600 of 10. Serial dilutions were then made to yield OD600
values of 1, 0.1, and 0.01. 10 μl of each dilution was then spotted onto synthetic
medium lacking uracil and tryptophan and containing either glucose or galactose as a
carbon source (Clontech).
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3.3.8 YEAST TWO-HYBRID INTERACTION ASSAY
To test TRBP-PKR interaction, full length K296R PKR was expressed as a GAL4
DNA-activation domain fusion protein from the pGAD424 vector and the AAAA and
DDDD TRBP point mutants were expressed as GAL4 DNA-binding domain fusion proteins
from the pGBKT7 vector. Full length AAAA and DDDD TRBP point mutants were
expressed as GAL4 DNA-activation domain fusion proteins from the pGADT7 vector and
GAL4 DNA-binding domain fusion proteins from the pGBKT7 vector to test TRBP-TRBP
interaction. The AAAA TRBP and DDDD TRBP pGBKT7 /pGADT7 construct pairs and
PKR/pGAD424 and AAAA (DDDD) TRBP/pGBKT7 construct pairs were co-transformed
into AH109 yeast cells (Clontech) and the transformed yeast cells were plated on double
dropout SD minimal medium lacking tryptophan and leucine. In order to check for the
transformants’ ability to grow on triple dropout media, transformed yeast cells were
grown to an OD600 of 2 in YPD media (yeast extract, peptone, and dextrose). 500 μl of
each culture was pelleted and resuspended in an appropriate amount of distilled water
to yield an OD600 of 10. Serial dilutions were then made to yield OD600 values of 1, 0.1,
and 0.01. 10 μl of each dilution was then spotted onto triple dropout SD minimal media
lacking histidine, tryptophan, and leucine in the presence of 10 mM 3-amino-1,2,4triazole (3-AT). Plates were incubated at 30oC for 5 days.

3.3.9 APOPTOSIS ASSAY

HeLa cells were grown to 50% confluency in six-well plates and co-transfected
with 200 ng of Flag TRBP AAAA or TRBP DDDD/pcDNA 3.1- and 200 ng of pEGFPC1
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(Clontech) using Effectene (Qiagen). Cells were also co-transfected with 200 ng BSIIKS+
(Agilent) and 200 ng pEGFPC1 as a control. The cells were observed for GFP fluorescence
24 hours after transfection using an inverted fluorescence microscope (EVOS® FL
Imaging System). Cells were treated with 25 μM sodium arsenite, and cellular
morphology was monitored at 1 hour intervals. 12 hours after treatment, the cells were
rinsed with ice-cold phosphate buffered saline (PBS) and fixed in 2% paraformaldehyde
for 10 minutes. Cells were washed twice in ice-cold PBS and permeabilized with 0.1%
Triton-X for 10 minutes, after which the cells were washed twice in ice-cold PBS. Cells
were stained with the DAPI nuclear stain (4,6-diamidino-2-phenylindole) at 0.5 μg/ml in
for 10 minutes at room temperature in the dark. The cells were rinsed once with PBS
and viewed under the fluorescent microscope.
At least 300 GFP-positive cells were counted as apoptotic or live based on their
morphology. Cells showing normal flat morphology were scored as live, while cells
showing cell shrinkage, membrane blebbing, rounded morphology and nuclear
condensation with intense fluorescence as apoptotic. The percentage of cells
undergoing apoptosis (Percent apoptosis) was calculated using the formula: (EGFPexpressing cells with intense DAPI nuclear staining/Total EGFP-expressing cells) x 100.

3.3.10 PKR-INHIBITION AND APOPTOSIS ASSAY
HeLa cells were grown on coverslips and transfected with 500 ng of wt PKR
pEGFPC1 and 20 ng pcDNA 3.1-, Flag TRBP AAAA/ pcDNA 3.1-, or Flag TRBP DDDD/
pcDNA 3.1- using Effectene (Qiagen). 24 hours after transfection, the cells were rinsed
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with ice-cold phosphate buffered saline (PBS) and fixed in 2% paraformaldehyde for 10
minutes. Cells were washed twice in ice-cold PBS and permeabilized with 0.1% Triton-X
for 10 minutes, after which the cells were washed twice in ice-cold PBS. The cover slips
were mounted in Vectashield mounting medium containing DAPI (Vector Laboratories).
Cells were then viewed under the fluorescence microscope (EVOS® FL Imaging System).
At least 500 EGFP-positive cells were scored as live or apoptotic as described in
‘Apoptosis Assay’.

3.3.11 ESTIMATION OF MITOCHONDRIAL MEMBRANE POTENTIAL.
HeLa cells were grown to 50% confluency in six-well plates and transfected with
500 ng of wt PKR pEGFPC1 and 20 ng pcDNA 3.1-, Flag TRBP AAAA/ pcDNA 3.1-, or Flag
TRBP DDDD/ pcDNA 3.1-. MitoPT® TMRM assay was performed using the
manufacturer’s instructions (ImmunoChemistry Technologies MitoPT® TMRM Assay Kit).
Green fluorescence (EGFP-PKR) and changes in red fluorescence (changes in
mitochondrial polarization) were observed under an inverted fluorescence microscope
(EVOS® FL Imaging System). At least 500 PKR expressing cells (GFP positive cells) were
scored as live or dead based on decreased or absent red fluorescence. The percentage
of cells undergoing apoptosis (Percent apoptosis) was calculated using the formula:
(EGFP- expressing cells with decreased or absent red fluorescence/Total EGFPexpressing cells) x 100.
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3.3.12 STATISTICAL ANALYSIS
Statistical significance of western blot quantifications and percent apoptosis were
determined by two-tailed Student’s T-test assuming equal variance or one-way ANOVA
followed by post-Hoc Tukey test respectively. Figure legends indicate the statistical test
used, and P-values are denoted by brackets and special characters. Alpha level was p =
0.05.

3.4 RESULTS
3.4.1 TRBP OVEREXPRESSION INHIBITS OXIDATIVE STRESS-INDUCED APOPTOSIS.
To evaluate TRBP’s effect on the cellular response to oxidative stress, we
established a stable HeLa-Tet off cell line that would conditionally overexpress FlagTRBP only when doxycycline was absent from the growth medium. A HeLa-Tet off cell
line with stably transfected empty vector pTRE2pur was established as a control.
We initially characterized 20 individual puromycin resistant clones and selected one
clone that showed the least expression of Flag-TRBP in the presence of doxycycline and
showed a good induction of Flag-TRBP expression in the absence of doxycycline. As seen
in Figure 3.1A, the Flag-TRBP expression is induced to high levels in a time dependent
manner after removal of doxycycline from the growth medium (lanes 2-5). We used
these cells for assaying the effects of TRBP overexpression on apoptosis induced by
oxidative stress. After the cells were grown in doxycycline-deficient growth medium for
24h, they were exposed to sodium arsenite to induce oxidative stress. The cells were
thus expressing high levels of Flag-TRBP when exposed to oxidative stress and this

86

allowed us to assay the effect of TRBP overexpression on cellular apoptosis and PKR
activation.
In order to compare the relative apoptosis in control and TRBP overexpressing
cells we used DNA fragmentation analysis. DNA fragmentation is a late marker of
apoptotic cells as the DNA is cleaved by caspase-activated DNases (CADs) into
nucleosomal fragments of 180 bp183. As seen in Figure 3.1B, the control cells stably
transfected with empty vector (EV-HeLa) showed high levels of DNA fragmentation in
response to sodium arsenite (lanes 5-8). In comparison, the cells overexpressing FlagTRBP (TRBP-HeLa) have significantly less DNA fragmentation after exposure to sodium
arsenite (lanes 1-4). These results indicate that TRBP overexpressing cells are
significantly protected from oxidative stress-induced apoptosis.
In order to further assess the protection from cellular apoptosis by TRBP
overexpression, we compared the cleavage of Poly-ADP Ribose Polymerase (PARP1) in
response to arsenite treatment. The 116 kDa protein PARP1 is cleaved into an 89kDa
fragment by Caspase-3 in response to apoptosis-inducing stimuli184. We measured and
quantified PARP1 cleavage in both sets of cells after treatment with arsenite (Figure
3.1C and 3.1D). As seen in Figure 3.1C, there is a steady increase in the levels of cleaved
PARP1 in the control (EV-HeLa) and TRBP-overexpressing (TRBP-HeLa) cells in a time
dependent manner. After 24 hours of arsenite exposure, there is significantly more
cleaved PARP1 in the EV-HeLa cells (Lane 4) as compared to the TRBP-HeLa cells (Lane
8). The percentage of cleaved PARP1 is about 90% in the HeLa cells (Figure 3.1D, 24 hr.),
and only about 45% in the TRBP-HeLa cells (Figure 3.1D, 24 hr.). These results indicate
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that caspase-3 activation and subsequent PARP1 cleavage is significantly impaired in
cells overexpressing TRBP, and demonstrate that TRBP overexpression protects the cells
from apoptosis in response to oxidative stress.

3.4.2 BOTH ERK AND JNK PHOSPHORYLATE TRBP IN RESPONSE TO OXIDATIVE STRESS
In order to determine if TRBP undergoes post-translational modifications in
response to stress signals with any functional implications on TRBP’s ability to inhibit
PKR, we performed western blot analysis of extracts from TRBP-HeLa cells exposed for
24 hours to sodium arsenite. The analysis revealed the presence of an additional FlagTRBP band with reduced electrophoretic mobility as indicated by an asterisk (Fig. 3.2A)
that increased in intensity from 8 to 12 hours after arsenite treatment and declined at
24 hours after treatment (Figure 3.2A, Flag-TRBP panel, Lanes 5 - 8). These results
suggested that the slow migrating Flag-TRBP band may be indicative of TRBP
phosphorylation at late time points after arsenite exposure. Interestingly, we also noted
that the strengthening of the TRBP doublet banding pattern from 8 to 12 hours after
treatment coincides with the gradual decrease in phosphorylated eIF2α levels at these
time points after sodium arsenite treatment (Figure 3.2B: p-eIF2α panel, Lanes 6-8) and
a decrease in phosphorylated PKR levels (Figure 3.2B: p-PKR panel, Lanes 5 -8). These
results suggest that TRBP phosphorylation may regulate PKR activation and consequent
eIF2α phosphorylation in response to arsenite.
To test this, we investigated if the slow migrating TRBP band resulted from
phosphorylation by using phosphatase treatment in the presence and absence of
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phosphatase inhibitors. Phosphatase treatment of cell extract prepared 8 and 12 hours
after arsenite treatment completely removed the stress-induced slow-migrating band
(Figure 3.2C, lanes 5 and 8), demonstrating that the slower mobility band (denoted ‘pTRBP’) did result from TRBP phosphorylation in response to oxidative stress. The p-TRBP
band persisted when the phosphatase treatment was performed in the presence of
phosphatase inhibitors, thereby confirming that the disappearance of the band in lanes
5 and 8 was indeed due to phosphatase activity and not due to the presence of any
contaminating proteolytic activity. These results indicate a possible link between the
timing of PKR activation and its eventual inactivation during cell stress and the timing of
TRBP phosphorylation in response to oxidative stress.
The Mitogen-activated protein kinase (MAPK) signaling pathways are activated in
response to diverse stimuli185, and elicit either pro-apoptotic or pro-survival cellular
responses. Previous studies have demonstrated that MAPKs such as the Extracellularsignal regulated Kinase (ERK 1/2) and c-Jun N-terminal kinase (JNK) play important roles
in mediating the cellular response to oxidative stress186. To test if ERK 1/2
phosphorylates TRBP in response to oxidative stress, we pretreated the Flag TRBP
overexpressing cells with the MEK inhibitor PD0325901, and exposed the cells to sodium
arsenite. In the samples not pretreated with PD0325901, we observed the p-TRBP band
at 8 and 12 hrs. after treatment (Figure 3.2D: TRBP panel, Lanes 1 -4).
Furthermore, we also observed that the increase in TRBP phosphorylation
closely mirrored the increase in phospho-ERK levels at 8, and 12 hours of treatment
(Figure 3.2D, p-ERK panel, Lanes 1-4). With the inhibition of ERK phosphorylation,

89

(Figure 3.2D, p-ERK panel, Lanes 5-8) the p-TRBP band is significantly diminished (Figure
3.2D, TRBP panel, Lanes 5-8). To test if JNK also phosphorylates TRBP in response to
oxidative stress, we pretreated the Flag TRBP overexpressing cells with the JNK inhibitor
SP600125, and exposed the cells to sodium arsenite. In the samples not pretreated with
SP600125, we observed the p-TRBP band at 8 and 12 hrs after treatment (Figure 3.2E:
TRBP panel, Lanes 1 -4). Furthermore, we also observed that the increase in TRBP
phosphorylation closely mirrored the increase in phospho-JNK levels at 8, and 12 hours
of treatment (Figure 3.2E, p-ERK panel, Lanes 1-4). With the inhibition of JNK
phosphorylation, (Figure 3.2E, p-JNK panel, Lanes 5-8) the p-TRBP band is completely
absent (Figure 3.2E, TRBP panel, Lanes 5-8). The results in Figures 3.2D and 3.2E suggest
that both ERK and JNK phosphorylate TRBP in response to oxidative stress.

3.4.3 EFFECT OF TRBP PHOSPHORYLATION ON CELLULAR RESPONSE TO STRESS
Having demonstrated that TRBP is phosphorylated by JNK and ERK 1/2 in
response to oxidative stress, we wanted to determine how TRBP phosphorylation
affects oxidative stress and PKR-mediated cellular apoptosis. To evaluate the
involvement of phosphorylation, we generated a phospho-defective TRBP point mutant
(TRBP AAAA) which contains alanine for serine substitution at 4 sites (S142, S152, S283,
S286) previously identified as MAPK/ERK 1/2 substrate sites181. Of these sites, S142 and
S152 have also been previously shown to be phosphorylated by JNK92. A phospho-mimic
TRBP point mutant (TRBP DDDD) was also generated by substituting aspartic acid for
serine at the same four sites (Figure 3.3A).
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To examine the effect of TRBP phosphorylation on oxidative stress-induced
apoptosis, we transfected HeLa cells with each TRBP phospho-mutant and observed
changes in the induction of apoptosis in response to oxidative stress. As seen in Figure
3.3B, the cells transfected with the empty vector (EV) alone showed 5.6% apoptosis (Untreated,
black bar) in the absence of stress which increased to 46.9% at 24 h after sodium arsenite
treatment (24 hrs, black bar). The DDDD TRBP phospho-mimic mutant showed significantly
reduced apoptosis in response to oxidative stress with only 29.1% cells undergoing apoptosis at
24 h after treatment (24 hrs, red bar).

Statistical analysis also showed a significant difference between the % apoptosis in the
cells expressing the empty vector as compared to the cells expressing the TRBP
phospho-mimic mutant, indicating that TRBP phosphorylation does have a protective
effect on cells during oxidative stress. Analysis of the % apoptosis in the cells expressing
the AAAA TRBP phospho-defective mutant to that of cells expressing EV showed no
statistical difference, highlighting the importance of phosphorylation for TRBP’s antiapoptotic activity.
We next examined the effect of TRBP phosphorylation on PKR-induced
apoptosis. An overexpression of active PKR in mammalian cells is sufficient to trigger
cellular apoptosis in the absence of any stress signals187,188. It has been previously
observed by us and others that PKR-EGFP fusion construct encodes a constitutively
active PKR, which induces apoptosis when transfected in mammalian cells189.
Thus, cells were transfected with a constitutively active PKR expression plasmid (wtPKR-EGFP+EV) or in combination with the TRBP AAAA phospho-defective or DDDD
phospho-mimic mutant and assayed for changes in apoptosis induced by active PKR. We
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used nuclear condensation as a hallmark sign of apoptosis as indicated by intense DAPI
fluorescence190. There is a significant amount of apoptosis at 87.5% (Figure 3.3C, wt
PKR, black bar) in transfected cells that express constitutively active PKR. The
percentage cell death is significantly reduced with the co-expression of both AAAA
phospho-defective (65.9 %) and DDDD phospho-mimic TRBP (49.5 %) mutants with PKREGFP (Figure 3.3C, wt PKR + AAAA and wt PKR + DDDD, blue and red bars). Consistent
with our previous results in Figure 3.3A, we also observe greater reduction in apoptosis
with expression of the TRBP phospho-mimic mutant, indicating that although AAAA
phospho-defective mutant can still inhibit PKR, the DDDD phospho-mimic mutant
inhibits PKR much more efficiently.
We further assayed apoptosis by using the mitochondrial membrane
depolarization as an early marker for apoptotic cells191. The effect of TRBP phosphomutants (TRBP AAAA or TRBP DDDD) on apoptosis induced by constitutively active PKREGFP was measured. Similar to our result in Figure 3.3C, we observed apoptosis (~75 %)
in cells expressing constitutively active PKR. Cells co-expressing the AAAA TRBP
phospho-defective mutant had a 16 % decrease in cell death compared to the cells
expressing PKR-EGFP alone, while the cells co-expressing the DDDD TRBP phosphomimic mutant had a 63% decrease in cell apoptosis compared to the cells expressing
PKR-EGFP alone. Taken together, these results clearly demonstrate that TRBP
phosphorylation is protective during oxidative stress, and this protection is mediated via
inhibition of PKR.
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3.4.4 TRBP PHOSPHORYLATION INHIBITS PKR’S KINASE ACTIVITY MORE EFFICIENTLY
To determine if protection from apoptosis was a direct result of enhanced PKR
inhibition by the phosphorylated TRBP isoform, we performed a yeast growth inhibition
assay using the INVSc1 S. cerevisiae yeast strain (Figure 3.4). The expression of active
PKR in S. cerevisiae suppresses yeast growth, and this growth inhibition can be reversed
by co-expression of PKR inhibitors such as the dominant negative PKR mutant,
K296R58,173,192. We introduced a galactose-inducible wt PKR yeast expression plasmid (wt
PKR/pYES2) in combination with K296R, wt TRBP, AAAA TRBP, or DDDD TRBP expression
plasmids (pYES3CT) into INVSc1 yeast cells. As expected, induction of PKR expression on
galactose-containing media inhibited yeast cell growth (+ GAL panel, wt PKR alone). We
also observed that co-expression of K296R or wt TRBP reversed the PKR-mediated
growth phenotype (+ GAL panel, K296R, wt TRBP) in accordance with previous reports
that have shown that K296R and TRBP inhibit PKR activity96,97. Interestingly, when we
co-expressed the phospho-deficient TRBP mutant (AAAA TRBP), it was unable to reverse
the growth phenotype (compare wt PKR alone to AAAA TRBP, + GAL panel) suggesting
that TRBP phosphorylation is crucial for TRBP’s ability to inhibit PKR.
On the other hand, co-expression of the phospho-mimic TRBP mutant (DDDD TRBP
reversed the PKR-mediated growth inhibition more efficiently as compared to wt TRBP.
These results indicate that phosphorylated TRBP inhibits PKR’s kinase activity in a more
efficient manner.
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3.4.5 STRESS-INDUCED TRBP PHOSPHORYLATION ENHANCES TRBP-PKR INTERACTIONS,
WHILE WEAKENING TRBP-TRBP INTERACTIONS.
To understand how stress-induced phosphorylation of TRBP affects its
interaction with PKR, we used the yeast-two hybrid system to test the strength of
interaction between PKR and TRBP phospho-mimic and phospho-defective point
mutants. The TRBP DDDD and TRBP AAAA point mutants were expressed in yeast as
GAL4 DNA binding domain fusion proteins (pGBKT7) with PKR was expressed as a GAL4
activation domain fusion protein. In this system, a stronger interaction between TRBP
and PKR is indicated by increased yeast growth in media lacking tryptophan, leucine,
and histidine in the presence of the imidazole glycerol-phosphate dehydratase
competitive inhibitor, 3-Amino-1,2,4-triazole (3-AT). As seen in Figure 3.5A, the TRBP
DDDD point mutant shows significantly stronger interaction with PKR as compared to
the TRBP AAAA point mutant, suggesting that the stronger PKR inhibition by DDDD TRBP
we observed in Figures 3.3 and 3.4 results from an enhanced TRBP-PKR interaction.
Since we showed enhanced interaction with PKR resulting in more efficient PKR
inhibition with the phospho-mimic DDDD TRBP mutant, we tested if we would also
observe significantly increased TRBP-PKR interaction in response to arsenite at 8 and 12
hours post-treatment when we observe the strongest TRBP phosphorylation (Figure
3.2A). We tested this by assaying if TRBP from treated cells interacts better with PKR in a
pull-down assay. As seen in Figure 3.5B, in the absence of stress signals there is weak
interaction between PKR and TRBP (Bound panels, Lane 2) which substantially decreases
at 2 and 4 hours (Bound panels, Lanes 3 and 4) due to PKR’s disassociation from TRBP in
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response to stress. We observed much stronger re-association between PKR and TRBP
at 8 hours and 12 hours after treatment (Bound panels, Lanes 5 and 6). A quantification
of the pull-down assay shown as a bar graph shows that both the reduction in TRBP-PKR
interaction after stress and the reassociation of TRBP with PKR at later time points after
stress is statistically significant. Thus, our results strongly support that TRBP’s
interaction with PKR and consequently its ability to inhibit PKR effectively during cell
stress is closely linked to its phosphorylation status.
Since stress-induced phosphorylation is essential for efficient PACT-PACT
interactions68, we investigated how phosphorylation affects TRBP-TRBP interactions. We
expressed both TRBP phospho-mutants in yeast as GAL4 DNA-binding domain fusion
proteins (pGBKT7) and GAL4 activation domain fusion proteins (pGADT7) and assayed
for the strength of TRBP AAAA and TRBP DDDD homomeric interactions by the amount
of yeast growth on nutrient deficient media in the presence of 3-AT. As seen in Figure
3.5C, yeast cells expressing both AAAA TRBP expression vectors show growth at all
dilutions, indicating strong homodimer interaction between unphosphorylated TRBP
proteins. In contrast to this, there was a complete absence of growth even at the most
concentrated dilution of yeast cells (10 OD) expressing both DDDD TRBP yeast
expression vectors, which indicates that TRBP phosphorylation is highly unfavorable to
the formation of TRBP homodimers.
We also examined TRBP AAAA and TRBP DDDD homomeric interactions in
mammalian cells using a co-immunoprecipitation assay. As seen in Figure 3.5D, we
observed that significantly less myc-DDDD TRBP was co-immunoprecipitated with Flag-
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DDDD TRBP (IP Myc panel, Lane 1) compared to the myc-AAAA TRBP coimmunoprecipitated with Flag-AAAA TRBP (IP Myc panel, Lane 3). The Flag panels
demonstrate that comparable amounts of Flag-DDDD TRBP (IP panel, Lane 1) and FlagAAAA TRBP (IP panel, Lane 3) were immunoprecipitated, thereby confirming that the
significant difference seen in co-immunoprecipitated bands reflects difference in TRBP
homomeric interactions. The absence of co-immunoprecipitated myc-DDDD or mycAAAA TRBP without co-expression of Flag-DDDD TRBP (IP, Lane 2) or Flag-AAAA TRBP
(IP, Lane 4) rules out any nonspecific immunoprecipitation.
Taken together, these results strongly demonstrate that stress-induced TRBP
phosphorylation significantly weakens homomeric interactions between TRBP molecules
while simultaneously enhancing TRBP-PKR interactions, which plays an important role in
attenuating sustained PKR activation during cell stress and inhibits excessive apoptosis.
The results presented here contribute to our understanding of how PKR activity is
regulated negatively at later time points after oxidative stress to prevent excessive
apoptosis.

3.5 DISCUSSION
Activation of PKR during cellular stress is regulated by PACT and TRBP, PACT
acting positively to activate PKR and TRBP acting negatively to suppress excessive PKR
activity60,67,180. Initially at early time points after stress, PACT activates PKR to aid
inhibition of protein synthesis via phosphorylation of eIF260,62,67. Our results presented
here, for the first time demonstrate that TRBP is phosphorylated by ERK 1/2 and JNK in
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response to oxidative stress at late time points and the phosphorylated TRBP inhibits
PKR’s kinase activity more efficiently to protect cells from apoptosis. In addition, the
enhanced PKR inhibition and protection from apoptosis by phospho-TRBP is brought
about by an increased interaction between phospho-TRBP and PKR as well as decreased
phospho-TRBP homomeric interactions. The timely downregulation of PKR activity and
eIF2 phosphorylation is achieved in part by induction of GADD34, a regulatory subunit
of protein phosphatase 1 (PP1)193,194.
Our data indicates that TRBP also plays an important role in the downregulation
of PKR activity. Thus, PKR activity during cell stress is dictated not only by stress-induced
changes in interactions between PACT and PKR, but also by interactions between PKR
and TRBP. TRBP interacts with both PACT and PKR and although TRBP phosphorylation
enhances its affinity for PKR while reducing the TRBP-TRBP interactions, we observed no
effect of TRBP phosphorylation on TRBP-PACT interactions (data not shown). On the
contrary, stress-induced PACT phosphorylation reduces the PACT-TRBP interactions
while increasing PACT-PACT interactions and PACT-PKR interactions, thereby leading to
PKR activation62,195. Strikingly, although TRBP and PACT are very homologous, the stressinduced phosphorylation affects the protein-protein interaction properties of PACT and
TRBP quite differently.
Based on our data, we present a schematic model for TRBP-mediated
downregulation of PKR activity at late time points after cellular stress. As depicted in
Figure 3.6, PKR and unphosphorylated TRBP interact under unstressed conditions in the
cell, preventing PKR activation, and eIF2α phosphorylation. Unphosphorylated TRBP also
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forms homodimers efficiently. In response to oxidative stress, PKR is activated by
phosphorylated PACT homodimers (not depicted) and eIF2 is phosphorylated to bring
about a transient protein synthesis inhibition. TRBP at this point remains
unphosphorylated, and efficiently forms TRBP-TRBP homodimers. Late after the onset of
the stressful event, ERK1/2 and JNK phosphorylate TRBP, leading to significantly
decreased TRBP-TRBP interactions, and increased TRBP-PKR interactions. Phospho-TRBP
interacts with PKR at significantly higher affinity to bring about efficient PKR
inactivation, and eIF2α is dephosphorylated. Phospho-TRBP does not form homodimers
efficiently and this could partly explain efficient PKR inhibition as it is established that
PKR is activated mainly by trans-autophosphorylation and PKR-PKR interactions. Thus,
monomeric phospho-TRBP could potentially function to inhibit PKR by preventing PKRPKR interactions.
The dsRBM motifs present in PKR, TRBP, and PACT possess the characteristic
alpha-beta-beta-beta-alpha fold that has two well-characterized functions to bind
structured RNA molecules and to mediate protein-protein interactions176,196. This motif
is widely distributed in eukaryotic proteins, as well as in proteins from bacteria and
viruses and the dsRBM-containing proteins are involved in a variety of cellular processes
ranging from RNA editing, nucleocytoplasmic transport, RNA localization, protein
phosphorylation in translational control, and contain a variable number
of dsRBM domains197. In addition, dsRBMs can also recognize non-RNA targets (proteins
and DNA), and act in combination with other dsRBMs and non-dsRBM motifs to play a
regulatory role in catalytic processes198. Our work presented here adds one more layer
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of complexity to the versatility of the dsRBM as it demonstrates that phosphorylation
sites residing outside the dsRBM influence the strength of protein-protein interactions
mediated via the dsRBMs. This also underscores the importance of optimal juxtaposition
of the multiple dsRBM motifs relative to each other in regulating protein interactions as
the phosphorylation of specific serines outside the motif can possibly bring about
significant changes in overall protein conformations. In other members of the diverse
family of dsRBM-containing proteins, the role of phosphorylation and post-translational
modifications in regulating interactions with RNA or proteins remains to be investigated
in future.
Our results on the effect of TRBP phosphorylation on PKR activity are in
agreement with Kim et al. who reported that phospho-TRBP efficiently inhibits PKR
during M-G1 transition to regulate cell cycle99. In this study, the phosphorylation of
TRBP during M-G1 transition was shown to be mediated by JNK. Of the four sites we
studied, S142 and S152 were also identified by Kim et al. to be phosphorylated by JNK
during M phase. ERK mediated phosphorylation of TRBP on S142, S152, S283, and S286
was reported in response to mitogenic signaling and was accompanied by a coordinated
increase in the levels of growth-promoting miRNAs and a reduction in the levels of
tumor suppressor let-7 miRNA181. TRBP phosphorylation has been reported to occur in
response to metabolic stress and inhibition of TRBP phosphorylation during metabolic
stress reduced inflammation and improved systemic insulin resistance and glucose
metabolism100,199. However, the exact functions of TRBP and PKR in high-fat dietinduced obesity and associated metabolic and inflammatory complications remains
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unclear and controversial101. TRBP plays an important pro-viral function in HIV infected
cells by regulating PKR activity and promoting HIV replication109,118. Any effect of TRBP
phosphorylation in HIV-infected cells also remains unexplored at present. Our work on
the impact of TRBP phosphorylation on the stress signaling pathway and cellular survival
thus presents an additional paradigm for exploring the existence and importance of
such TRBP-mediated regulatory mechanisms in virus infected cells as well as miRNA
expression and function in response to cellular stress.
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Figure 3.1: TRBP overexpression protects cells from arsenite-induced apoptosis.
(A) Establishment of a stable doxycycline-inducible HeLa cell line overexpressing FlagTRBP. HeLa-Tet off (Clontech) cells were transfected with either FlagTRBP/pTRE2pur
expression construct or pTRE2pur (Clontech) empty vector (EV). Puromycin resistant
clones were isolated, characterized, and one clone (TRBP-HeLa) that showed inducible
expression of FlagTRBP was selected for further studies. Induction of FlagTRBP
expression after removal of doxycycline from the growth medium at indicated time
points is shown. Western blot analysis of cell lysates using 50 μg of total protein was
performed using anti-Flag and anti-β-actin antibodies. The black line between lanes 3
and 4 represents where different lanes from the same western blot were joined.
(B) DNA Fragmentation Analysis. TRBP-HeLa cells overexpressing FlagTRBP (Lanes 1 -4)
or EV-HeLa control cells (Lanes 5 -8) were treated with 10 μM sodium arsenite for 48,
72, and 96 hours, fragmented DNA was isolated and analyzed. M: 100-bp ladder, Lanes
1 & 5: 48 hr treatment. Lanes 2 & 6: 72 hr treatment, Lanes 3 & 7: 96 hr treatment, and
Lanes 4 & 8: untreated cells.
(C) Analysis of PARP cleavage in response to arsenite treatment. TRBP-HeLa and EVHeLa cells were treated with 25 μM sodium arsenite for the indicated time points, and
western blot analysis using anti-PARP antibody was performed on cell lysates containing
50 μg of total protein to assess increases in poly ADP-ribose polymerase (PARP1)
cleavage. Western blot was also performed with anti-GAPDH antibody to ensure equal
protein in all samples.
(D) Quantification of PARP cleavage. PARP1 and cleaved PARP1 bands were quantified
using ImageQuant TL Software. The percentage of cleaved PARP1 was calculated as
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Figure 3.1 (continued) (cleaved PARP1 band intensity/cleaved + uncleaved bands
intensities) X 100. Bars represent percentages of cleaved PARP1 from 3 independent
experiments. Error bars represent standard deviation (S.D.) from three experiments.
Student’s t tests were performed to determine statistical significance – ns: not
significant, asterisk: P value of 0.000352
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Figure 3.2: TRBP is phosphorylated by ERK and JNK in response to arsenite-induced oxidative stress.
(A) TRBP’s electrophoretic mobility shifts in response to sodium arsenite treatment. Western blot analysis of 50 μg protein per
lane from HeLa-TRBP cells treated with 10 μM sodium arsenite at the indicated time points is shown. Western blot analysis was
performed with anti-Flag and anti-β actin antibodies. The slower migrating TRBP band at 8h, and 12h is indicated by an asterisk. The
line between lanes 1 and 2 as well as between lanes 3 and 4 represents where lanes from the same western blot were joined.
(B) PKR phosphorylation and eIF2α phosphorylation kinetics in response to sodium arsenite treatment. HeLa cells were treated
with 10 µM sodium arsenite and cell extracts were prepared at the indicated time points. PKR and eIF2α phosphorylation status at
each time point was determined by a western blot analysis using anti-phospho-PKR and anti-phospho-eIF2α specific antibodies using

Figure 3.2 (continued) 100 µg and 10µg of total protein respectively. Each blot was subsequently stripped and re-probed with antieIF2α or anti-PKR antibody to ensure equal loading in all lanes.
(C) TRBP is phosphorylated in response to oxidative stress. Extracts from untreated, and 8h, or 12h arsenite-treated TRBP-HeLa
cells were prepared in the presence or absence of phosphatase inhibitor (PPi) as indicated above the lanes and subsequently treated
with phosphatase (Ptase) or left untreated as indicated. Western blot was performed with anti-Flag antibody followed by anti- βactin antibody.
(D) ERK is phosphorylated in response to oxidative stress and phosphorylates TRBP. TRBP overexpressing TRBP-HeLa cells were
treated with 10 μM arsenite alone or in combination with the MEK inhibitor PD0325901 for 24 hours. Cell extracts were made at the
indicated time points, and western blot analysis was performed using anti-Flag, anti-phospho-ERK, anti-total ERK, and anti-GAPDH
antibodies.
(E) JNK is phosphorylated in response to oxidative stress and phosphorylates TRBP. TRBP overexpressing TRBP-HeLa cells were
treated with 10 μM arsenite alone or in combination with the MEK inhibitor SP600125 for 24 hours. Cell extracts were made at the
indicated time points, and western blot analysis was performed using anti-Flag, anti-phospho-JNK, anti-total JNK, and anti-GAPDH
antibodies.
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Figure 3.3: TRBP phosphorylation inhibits PKR-mediated apoptosis during cell stress.
(A) Schematic representation of TRBP phosphorylation sites. Blue boxes represent the
three double-stranded RNA binding motifs (dsRBMs), M1, M2, and M3. Red vertical lines
represent previously identified ERK 1/2 phosphorylation sites at S142, S152, S283, and
S286.
(B) Expression of phospho-mimic TRBP protects cells during oxidative stress. HeLa cells
were transfected with 200ng pEGFPC1 (EV) alone (black bars) or with 200ng each of
pEGFPC1 and FlagTRBP AAAA/pcDNA 3.1- (blue bars) or with 200ng each of pEGFPC1
and FlagTRBP DDDD/pcDNA 3.1- (red bars). 24 hours after transfection, the cells were
treated with 25 μM sodium arsenite, fixed and stained with DAPI nuclear stain. At least
300 EGFP-positive cells were scored apoptotic or live based on nuclear condensation
indicated by intense DAPI nuclear staining and cell morphology. The percentage of cells
undergoing apoptosis (% apoptosis) was calculated using the formula: (EGFP- expressing
cells with intense DAPI nuclear staining/Total EGFP-expressing cells) x 100. Bars
represent averages ± S.D. from three independent experiments. One-way ANOVA
followed by post-hoc Tukey test was performed, ns: not significant, asterisk: P-value of
0.016.
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Figure 3.3 (continued) (C) and (D) Phospho-mimic TRBP inhibits PKR mediated
apoptosis more efficiently than phospho-defective TRBP (C) HeLa cells were plated on
coverslips and transfected with 500ng of wt PKR/pEGFPC1 and 20ng of empty vector
pCDNA3.1- (wt PKR; black bar) or with 500ng of wt PKR/pEGFPC1 + 20 ng of Flag TRBP
AAAA/ pcDNA 3.1- (blue bar) or 500ng of wt PKR/pEGFPC1 + 20ng of Flag TRBP DDDD/
pcDNA 3.1- (red bar). 24 hours after transfection, the cells were fixed and mounted in
Vectashield mounting media with DAPI nuclear stain. Representative fluorescent
micrographs of HeLa cells transfected with wt PKR pEGFPC1 alone (Panel A), or in
combination with Flag TRBP AAAA/ pcDNA 3.1- (Panel B) or Flag TRBP DDDD/ pcDNA 3.1(Panel C) are shown. At least 500 EGFP-PKR expressing cells were scored as apoptotic
Figure 3.3 (continued) (white arrows) or live (white arrowheads) based on nuclear
condensation indicated by intense DAPI staining and cellular morphology. The
percentage of cells undergoing apoptosis was determined as described in (A). Bars
represent averages ± S.D. from three independent experiments. One-way ANOVA
followed by post-hoc Tukey test was performed, asterisk *: P-value 0.0034, double
asterisk **: P-value 0.0002, #: P-value 0.0134. (D) Phospho-mimic TRBP expression
abrogates mitochondrial depolarization during PKR-mediated apoptosis. HeLa cells
were plated on coverslips and transfected with 500ng of wt PKR/pEGFPC1 and 20ng of
empty vector pCDNA3.1- (wt PKR; black bar) or with 500ng of wt PKR/pEGFPC1 + 20 ng
of Flag TRBP AAAA/ pcDNA 3.1- (blue bar) or 500ng of wt PKR/pEGFPC1 + 20ng of Flag
TRBP DDDD/ pcDNA 3.1- (red bar). 24 hours after transfection, changes in the
mitochondrial potential of transfected cells were assessed using the MitoPT TMRM
Assay kit and observed by fluorescence microscopy. Representative fluorescent
micrographs of the cells transfected with wt-PKR pEGFPC1 alone (wt-PKR-EGFP + EV,
Panel A), and AAAA TRBP (wt-PKR-EGFP + AAAA, Panel B) or DDDD TRBP (wt-PKR-EGFP +
DDDD, Panel C) are represented. At least 500 PKR expressing cells (GFP positive cells)
were scored as live (white arrowheads) or dead (white arrows) based on decreased or
absent red fluorescence. The percentage of cells undergoing apoptosis (% apoptosis)
was calculated using the formula: (EGFP- expressing cells with decreased or absent red
fluorescence/Total EGFP-expressing cells) x 100. Bars represent averages ± S.D. from
three independent experiments. One-way ANOVA followed by post-hoc Tukey test was
performed, asterisk *: P-value 0.0108, double asterisk **: P-value 0.0003, #: P-value
0.0002.

106

Figure 3.4: The phosphorylated TRBP isoform efficiently reverses PKR’s growth
inhibition phenotype in yeast. (A) Yeast growth inhibition assay. Yeast INVSc1 cells
were co-transformed with wt PKR/pYES2 and empty vector pYES3CT (PKR alone), wt
PKR/pYES2 and K296R PKR/pYES3CT (PKR+K296R), wt PKR/pYES2 and wt TRBP/pYES3CT
(PKR+wtTRBP), wt PKR/pYES2 and AAAA TRBP/pYES3CT (PKR+AAAA), or wt PKR/pYES2
and DDDD TRBP/pYES3CT (PKR+DDDD). Ten microliters of transformed yeast cells (OD 600
= 10, 1, 0.1, 0.01) were spotted on double dropout media (-uracil, - tryptophan) with
either glucose (+GLU) or galactose (+GAL) as sole carbon source. Plates were incubated
for three days at 30oC. Transformation of INVSc1 with wt PKR/pYES2 and empty vector
pYES3CT served as a control showing growth inhibition on galactose plates, while
transformation with wtPKR/pYES2 and K296R PKR/pYES3CT served as a positive control
for inhibition of PKR and a reversal of growth inhibition phenotype.
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Figure 3.5: TRBP phosphorylation strengthens PKR-TRBP interaction and weakens TRBP-TRBP interaction.
(A) Phosphomimic TRBP mutant interacts stronger with PKR compared to the phosphodefective TRBP mutant in yeast two-hybrid
assay. PKR/ pGAD424 and either AAAA TRBP/pGBKT7, or DDDD TRBP/pGBKT7 were co-transformed into AH109 yeast cells and
selected on SD double dropout media (-tryptophan, - leucine). Ten microliters of transformed yeast cells (OD600 = 10, 1, 0.1, 0.01)
were spotted on SD triple dropout media (-tryptophan, - leucine, - histidine) containing 10 mM 3-amino-1,2,4-triazole (3-AT).
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Figure 3.5 (continued) Plates were incubated for 5 days at 30oC. Transformation of PKR in pGAD424 and pGBKT7 empty vector
served as a negative control.
(B) Changes in TRBP association with PKR. Flag TRBP overexpressing cells were treated with 25 μM sodium arsenite for the
indicated time points. Cell extracts were prepared in the presence of a phosphatase inhibitor and 25 μg of cell extract was incubated
with 500 ng of pure recombinant hexahistidine (His)-tagged PKR immobilized on Ni2+-agarose beads. After washing the beads, PKRassociated Flag TRBP was analyzed by SDS polyacrylamide gel electrophoresis followed by western blot analysis with anti-Flag
antibody. Western blot analysis was also performed with anti-His antibody to ensure equal His- PKR in each sample. 25 μg of cell
extract was also analyzed by western blot analysis with anti-Flag and anti-GAPDH antibodies to ensure equal addition of cell lysate
for each pull down (Input). Quantification of TRBP-PKR pull down: Band intensities were quantified using ImageQuant TL Software,
and the ratios of bound TRBP to bound PKR across all samples were calculated and normalized to the band intensities of Flag-TRBP
input for each sample. Bound TRBP/his-PKR ratios for all samples were all expressed relative to the control sample (Lane 2).
Averages from three independent experiments are plotted as bar graphs ± S.D. One-way ANOVA followed by post-hoc Tukey test
was performed, asterisk *: p value 0.0000012 and double asterisk **: p value 0.0066374.
(C) Phosphomimic TRBP mutant shows stronger homomeric interaction compared to the phosphodefective TRBP mutant in yeast
two-hybrid assay. AAAA TRBP or DDDD TRBP point mutants in pGADT7 and pGBKT7 were co-transformed into AH109 yeast cells and
selected on SD double dropout media (-tryptophan, -leucine). Ten microliters of transformed yeast cells (OD600 = 10, 1, 0.1, 0.01)
were spotted on SD triple dropout media plate (tryptophan, -leucine, -histidine) containing 10 mM 3-amino-1,2,4-triazole (3-AT).
Plates were incubated for 5 days at 30oC. Transformation of pGADT7 and pGBKT7 empty vectors served as a negative control.
(D) Phosphomimic TRBP mutant shows stronger homomeric interaction compared to the phosphodefective TRBP mutant in
mammalian cells. HeLa cells were transfected with either myc TRBP DDDD/ pcDNA 3.1- and Flag TRBP DDDD/ pcDNA 3.1- or Flag
TRBP AAAA/ pcDNA 3.1- and myc TRBP AAAA/ pcDNA 3.1-. The cells were harvested 24 hours after transfection, and Flag TRBP AAAA
or DDDD was immunoprecipitated using anti-Flag monoclonal antibody conjugated agarose beads. The co-immunoprecipitation of
myc-TRBP was analyzed by western blot analysis with an anti-myc antibody (IP: x Myc panel). Blot was subsequently stripped and reprobed with anti-Flag antibody to ensure equal Flag-TRBP immunoprecipitation from each sample (IP: x Flag panel). Equal AAAA
TRBP and DDDD TRBP expression in all samples was tested by western blot analysis of equal amounts of total cell lysate with antimyc, and anti-Flag antibodies (Input: x Myc and x Flag panels).

Figure 3.6: A schematic model of PKR-TRBP interaction in response to oxidative stress.
As previously established60,95,176, in the absence of stress, TRBP heterodimerizes with
PKR, PKR is catalytically inactive and eIF2α is not phosphorylated. At early time points
after ER stress, TRBP dissociates from PKR and PKR is activated leading to its
autophosphorylation and eIF2α phosphorylation. At late time points after stress, TRBP is
phosphorylated by ERK and JNK and interacts with PKR with higher affinity. The cells
recover by forming TRBP-PKR heterodimers and turning off PKR and eIF2α
phosphorylation. Phosphorylated TRBP largely remains monomeric as TRBP-TRBP
interactions are weakened by phosphorylation of TRBP.
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CHAPTER 4

CONTRIBUTION OF THE TWO DSRBM MOTIFS TO THE DOUBLE-STRANDED
RNA BINDING AND PROTEIN INTERACTIONS OF PACT4

4

Chukwurah E., Willingham V., Singh M., Castillo D., and Patel RC Submitted to Journal of
Cellular Biochemistry 2017.
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4.1. ABSTRACT
PACT is a stress-modulated activator of protein kinase PKR (protein kinase,
RNA activated), which is involved in antiviral innate immune responses and stressinduced apoptosis. Stress-induced phosphorylation of PACT is essential for PACT's
increased association with PKR leading to PKR activation, phosphorylation of
translation initiation factor eIF2α, inhibition of protein synthesis, and apoptosis.
PACT-induced PKR activation is negatively regulated by TRBP (Transactivation
response element RNA-binding protein), which dissociates from PACT after PACT
phosphorylation in response to stress signals. The conserved double-stranded RNA
binding motifs (dsRBMs) in PKR, PACT, and TRBP mediate protein-protein
interactions, and the stress-dependent phosphorylation of PACT changes the relative
strengths of PKR-PACT, PACT-TRBP, and PACT-PACT interactions to bring about a
timely and transient PKR activation. This regulates the general kinetics as well as level
of eIF2 phosphorylation, thereby influencing the cellular response to stress either
as recovery and survival or elimination by apoptosis. In the present study, we
evaluated the effect of specific mutations within PACT’s two evolutionarily conserved
dsRBMs on dsRNA-binding, and protein-protein interactions between PKR, PACT, and
TRBP. Our data shows that the two motifs contribute to varying extents in dsRNA
binding, and protein interactions. These findings indicate that although the dsRBM
motifs have high sequence conservation, their functional contribution in the context
of the whole protein needs to be determined by mutational analysis. Furthermore,
using a PACT mutant that is deficient in PACT-PACT interaction but competent for
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PACT-PKR interaction, we demonstrate that PACT-PACT interaction is essential for
efficient PKR activation.

4.2 INTRODUCTION
PACT is a double-stranded RNA binding protein that was identified originally as a
Protein Activator of PKR (protein kinase, RNA activated: encoded by the Eif2ak2 gene) in
human cells and later as PKR associated protein (RAX) in mouse. The gene that encodes
PACT is designated as Prkra and recently several mutations that lead to the movement
disorder dystonia have been described in the Prkra gene. PACT and RAX proteins are
mostly identical with only 6 out of 313 residues being different with 4 of these
substitutions being conservative. Initial studies on PACT focused on its ability to induce
the autophosphorylation and activation of the interferon (IFN)-inducible, doublestranded (ds) RNA dependent serine/threonine protein kinase (PKR) in response to
various stress signals. Activation of PKR results in phosphorylation of eukaryotic protein
synthesis initiation factor 2α (eIF2α) leading to an inhibition of protein synthesis.
PKR is expressed ubiquitously and mediates IFN’s antiviral actions in virally
infected cells as well as regulates cellular survival and apoptosis in response to stress in
uninfected cells. PKR's kinase activity remains latent until one of its activators bring
about a conformational change by direct binding to cause its enzymatic activation108.
During the replication of several viruses dsRNA is produced, which binds to PKR’s two
dsRNA-binding motifs (dsRBMs)45,175,200 to activate PKR and unmask the ATP-binding
site50 to promote autophosphorylation48. The two dsRBMs also mediate dsRNA-
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independent protein-protein interactions with other proteins that carry similar
domains176,177. Among these proteins, PACT functions to activate PKR in response to
stress signals and in the absence of dsRNA58,60 and TAR RNA-binding protein (TRBP)
serves as an inhibitor.
PACT contains three copies of dsRBM (Figure 1.3), of which the two aminoterminal motifs (M1 and M2) bind to dsRNA and also to dsRBMs of PKR. The third
carboxy-terminal motif 3 (M3) lacks the conserved lysines required for dsRNA-binding
and thus does not bind dsRNA. M3 is also dispensable for interaction with PKR’s dsRBM
motifs but is essential for PKR activation and interacts with a specific region in its kinase
domain63,64. Although purified, recombinant PACT can activate PKR by direct interaction
in vitro58, PACT-dependent PKR activation in cells occurs in response to stress signals59–62
such as arsenite, peroxide, growth factor withdrawal, thapsigargin, and tunicamycin,
and leads to phosphorylation of the translation initiation factor eIF2 and cellular
apoptosis59–61. PACT (and its murine homolog RAX) are phosphorylated in response to
stress leading to its increased association with PKR59–61. The stress-induced
phosphorylation site in PACT is at serine 287 (S287) and a constitutive phosphorylation
at serine 246 (S246) is required for S287 phosphorylation in response to oxidative stress.
The phosphorylation of S287 in response to oxidative stress increases the PACT-PKR and
PACT-PACT interactions but decreases PACT-TRBP interactions promoting PKR
activation. TRBP also has three dsRBMs; the first two are true dsRBMs and interact with
dsRNA, while the third carboxy-terminal dsRBM does not bind dsRNA but mediates
TRBP’s interactions with other proteins such as Dicer, and Merlin91,123,178. TRBP inhibits
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PKR by interacting with dsRNA and sequestering it away from PKR as well as by forming
PKR-TRBP heterodimers95,120. In the absence of viral infections and stress signals, TRBP
forms heterodimers with both PKR and PACT, preventing their association and PACTmediated PKR activation97,180. PKR activation in response to stress signals is thus tightly
regulated by PACT and TRBP, both regulating its catalytic activity by a direct
interaction180,195. As the dsRBMs in PKR, PACT, and TRBP mediate protein-protein
interactions201, these three proteins form both heterodimers as well as homodimers and
the stress-dependent phosphorylation of PACT changes the relative strengths of PKRPACT, PACT-TRBP, and PACT-PACT interactions to bring about a timely and transient PKR
activation with precise control68,195. This regulates the general kinetics as well as level of
eIF2 phosphorylation thereby influencing the cellular response to stress either as
recovery and survival or elimination by apoptosis179.
In this report, we examined the contribution of specific conserved amino acids
within the two amino-terminal dsRBM domains in PACT to its dsRNA-binding and
protein-protein interaction activities. Our results identify the conserved lysines and
specific hydrophobic amino acids within the two dsRBMs that are important for dsRNAbinding and protein-protein interactions respectively. In addition, the work underscores
the importance of PACT-PACT interactions in PKR activation following oxidative stress as
a phosphomimetic PACT mutant that is incapable of facilitating PACT-PACT interactions
fails to activate PKR and induce apoptosis. The results shed light on the mechanism of
PKR activation by PACT.
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4.3 MATERIALS AND METHODS
4.3.1 REAGENTS AND CELL LINES
HeLaM and COS-1 cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10% Fetal Bovine Serum and penicillin/streptomycin. Transfections
were performed with the Effectene Transfection Reagent (Qiagen) per the
manufacturer’s instructions.

4.3.2 PLASMIDS
The TRBP/pGBKT7, K296R PKR/pGBT9, Flag PACT S246D S287D (DD PACT)/
pcDNA 3.1-, wt PACT/BSIIKS+, Flag PACT/pCMV2, wt PACT/VP16 and wt PACT/GAL4
expression plasmids were prepared as previously described. The M1 (K84E, K88E,
A91E, A92D, L99E), and M2 (K177A, K181E, A184E, A185E, and F192E) point
mutations were introduced into wt PACT using the Gene Editor Site Directed
Mutagenesis Kit (Promega). After the sequence of each point mutant was verified,
the point mutants in BSIIKS+ were subcloned into the pGBKT7 and pGADT7 (Takara
Bio USA, Inc) yeast expression vectors at the NdeI and BamHI restriction sites.
The Flag-tagged L99E S246D S287D (DD-L99E) PACT triple point mutant in BSIIKS+
(Agilent Technologies) was generated by a three-piece ligation of the NdeI – EcoRI
restriction fragment from L99E BSIIKS+, EcoRI – EcoRI restriction fragment from DD
PACT pcDNA 3.1-, and the NdeI – EcoRI cut Flag BSIIKS+ fragment. The Flag tagged
triple mutant from BSIIKS+ was then introduced into the XbaI – EcoRI sites of the
pcDNA 3.1- expression vector (Invitrogen).
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4.3.3 DSRNA BINDING ASSAY
In vitro translated, 35S-labeled PACT proteins (wt, PACT M1 and M2 mutants)
were synthesized using the TNT® T7 Coupled Reticulocyte Lysate System (Promega).
The dsRNA-binding activity of each mutant was measured by the previously
described poly(I)·poly(C)–agarose binding assay [Patel and Sen, 1992]. 4 μl of the
translation products were diluted with 25 μl of binding buffer [20 mM Tris–HCl, pH
7.5, 0.3 M NaCl, 5 mM MgCl2, 1 mM DTT, 0.1 mM PMSF, 0.5% Igepal, 10% glycerol],
mixed with 25 μl of poly(I)·poly(C) – agarose beads and incubated at 30°C for 30
minutes. The beads were subsequently washed four times with 500 μl of binding
buffer and the proteins bound to the beads after the washes were analyzed by SDS–
PAGE and autoradiography. The T (Total) lanes represent the total synthesized 35Slabeled proteins from the rabbit reticulocyte lysate, and the B (Bound) lanes
represent the proteins that remained bound to the poly(I).poly(C) – agarose beads
after washes. The interaction of each PACT protein with dsRNA was quantified using
ImageQuant (GE Healthcare) by analyzing the band intensities of the total and bound
PACT proteins. The percentage of the PACT protein bound to poly(I)·poly(C) – agarose
beads was calculated from the band intensity values using this formula:
% Binding = (100 * band intensity of protein in the Bound lane)/(band intensity of
protein in the Total Lane). The calculated percentages were then plotted on bar
graphs. The poly(I)·poly(C)–agarose binding assay was also performed with in vitro
translated 35S-labelled firefly luciferase protein to demonstrate specific interaction
between the PACT proteins and the poly(I).poly(C) synthetic dsRNA.
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4.3.4 YEAST TWO-HYBRID INTERACTION ASSAYS
To test the interaction between the various indicated PACT point mutants and
PKR, full length K296R PKR was expressed as a GAL4 DNA binding domain fusion protein
from the pGBT9 vector while the PACT M1 and M2 mutants were expressed as GAL4
DNA activation domain fusion proteins from the pGADT7 vector.
The PKR/PACT mutant construct pairs were co-transformed into AH109 yeast
cells (Takara Bio USA) using the lithium acetate method192, which were plated on double
dropout synthetic defined (SD) minimal media plates lacking tryptophan and leucine.
The transformants were grown to an OD600 of 2 in YPD (yeast extract, peptone and
dextrose) media, and 500 μl of each culture was pelleted and resuspended in an
appropriate amount of distilled water to yield an OD600 of 10. Serial dilutions were then
made to yield OD600 values of 1, 0.1, 0.01. 10 μl of each serial dilution was spotted on
triple dropout SD media plates lacking histidine, tryptophan and leucine and incubated
at 30oC for 4 days. AH109 cells were also co-transformed with wt PACT/pGADT7 and
K296R/pGBT9 as a positive control, and with either A91E PACT/pGADT7, A92D
PACT/pGADT7, A184E PACT/pGADT7, A185E PACT/pGADT7, or F192E PACT/pGADT7 and
pGBKT7 as negative controls.
The relative strengths of the homomeric interactions of the PACT M1 and M2
point mutants were assayed by co-transforming AH109 yeast cells with the PACT
mutants expressed as both GAL4 DNA binding and activation domain fusion proteins
from the pGBKT7 and pGADT7 vectors. Similarly, the strengths of the PACT mutants’
heteromeric interaction with TRBP were tested by co-transforming the yeast cells with
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the PACT mutants expressed as GAL4 activation domain fusion proteins from the
pGADT7 vector and TRBP expressed as a GAL4 DNA binding domain fusion protein from
the pGBKT7 vector.
Selection of double transformant yeast cells and preparation of serial dilutions
was carried out as previously described, and the serial dilutions were spotted on triple
dropout media lacking histidine, tryptophan, and leucine in the presence of 10 mM 3amino-1,2,4-triazole (3-AT), a competitive inhibitor of histidine synthesis. The plates
were incubated at 30oC for 4 days. As positive controls, AH109 cells were transformed
with wt PACT/pGADT7 and wt PACT/pGBKT7 and wt PACT/pGADT7 and TRBP/pGBKT7
for the PACT homodimer interaction and PACT-TRBP heterodimer interaction
respectively.
For negative controls for the PACT-PACT homodimer yeast two-hybrid
experiments, AH109 cells were co-transformed with either A91E PACT/pGBKT7, A92D
PACT/pGBKT7, A184E PACT/pGBKT7, A185E PACT/pGBKT7, or F192E PACT/pGBKT7 and
pGADT7 vectors. Negative controls for the PACT-TRBP heterodimer yeast two-hybrid
experiments were AH109 yeast cells co-transformed with either the A91E
PACT/pGADT7, A92D PACT/pGADT7, A184E PACT/pGADT7, A185E PACT/pGADT7, or
F192E PACT/pGADT7 and pGBKT7 expression vectors.

4.3.5 MAMMALIAN TWO HYBRID INTERACTION ASSAY
Sequences encoding the L99E, S246D S287D (DD), or L99E S246D S287D (DDL99E) PACT point mutants were introduced into the pSG424 expression construct to
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generate an in-frame fusion of each protein to the GAL4 transcription DNA binding
domain (GAL4 DBD). In frame fusions of each protein to the activation domain of the
herpes simplex virus protein VP16 were also generated by introducing the sequences
into the pVP16AASV19N vector (VP16 AD).
COS-1 cells were transfected with 200 ng of each GAL4 DBD and VP16 AD
construct pair and 200 ng of the pG5Luc (Firefly luciferase) reporter construct using the
Effectene transfection reagent (Qiagen). The cells were also transfected with 1 ng of the
pRL Null vector (Renilla luciferase) (Promega) to normalize for transfection efficiency.
The cells were harvested 24 hours after transfection and assayed for firefly and Renilla
luciferase activity using the Dual-Luciferase® Reporter Assay System (Promega).

4.3.6 APOPTOSIS ASSAY
HeLaM cells were grown to 30% confluency in six-well plates and transfected
with 300 ng of Flag wt PACT/pCMV2, Flag DD PACT/pcDNA 3.1-, or Flag L99E DD
PACT/pcDNA 3.1- and 200 ng of pEGFPC1 (Takara Bio USA) using the Effectene
Transfection reagent (Qiagen). As a control, cells were transfected with 300 ng BSIIKS+
(Agilent Technologies) and 200 ng pEGFPC1.
The cells were observed for EGFP fluorescence 24 hours after transfection using
an inverted fluorescent microscope (EVOS®FL Imaging System, Thermo Fisher Scientific),
at which time they were washed twice with PBS and fixed in 4% paraformaldehyde for 5
minutes. The cells were subsequently washed with PBS and incubated with DAPI at 0.5
μg/ml in PBS for 10 minutes at room temperature. The cells were washed again in PBS
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and viewed under the fluorescent microscope. At least 300 GFP positive cells were
scored as apoptotic or non-apoptotic based on their morphology. Cells showing normal
flat morphology were scored as non-apoptotic, while cells showing cell shrinkage,
membrane blebbing, round morphology and nuclear condensation with intense DAPI
fluorescence were scored as apoptotic. The percentage of cells that underwent
apoptosis (% Apoptosis) was calculated using the formula: (EGFP-positive cells with
intense DAPI nuclear fluorescence/Total EGFP-positive cells) * 100.

4.3.7 STATISTICAL ANALYSES
Statistical significance of the dsRNA-binding quantifications, percent apoptosis, and
results from the mammalian two-hybrid interaction assay were determined by Student’s
T test or one-way ANOVA followed by post-hoc Tukey test as indicated in the figure
legends. P-values are denoted by brackets and special characters. Alpha level was p =
0.05.

4.4 RESULTS
The high-affinity interaction between PKR and PACT is mainly mediated by
PACT’s M1 and M2 motifs and M3 motif is dispensable for PKR-PACT interaction but is
essential for PKR activation63,64. The M1 and M2 motifs are also involved in dsRNA
binding via the conserved dsRBMs, which possess the characteristic amphipathic helix
also present in PKR49,202. Specific lysines on the charged side of this amphipathic helix
are important for dsRNA-binding, whereas hydrophobic amino acids on the opposite
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side are important for the protein-protein interactions. In order to characterize the
contribution of specific amino acids within the M1 and M2 motifs to dsRNA-binding and
PKR-PACT, TRBP-PACT, and PACT-PACT interactions, we created point mutations using
site-directed mutagenesis. As shown in Fig. 4.1 A, five residues were mutated
individually in M1 and M2. The selected residues are conserved in the M1 and M2
motifs of both PACT and TRBP (Fig. 4.1 B). We tested the effect of these mutations on
PACT’s dsRNA-binding (Fig. 4.1 C and D). Mutations in both M1 and M2 affected dsRNA
binding, but the M1 mutations showed a more drastic reduction in dsRNA binding
where all five mutations reduced the dsRNA binding to less than 20% of the wild type
PACT. The mutations in M2 showed a moderate effect with reduced dsRNA binding that
ranged from 15% to 65% of the wild type PACT. These results indicate that the M1 motif
contributes most to the dsRNA binding activity and M2 motif serves a supplementary
role.
The dsRBMs are also involved in mediating protein-protein interactions in a
dsRNA independent manner176. To understand the role of the hydrophobic residues
within the M1 and M2 motifs in mediating protein-protein interactions, we tested the
direct interactions of the point mutants with PKR, PACT, and TRBP using a yeast two
hybrid assay. Specifically, the three hydrophobic residues have been previously shown
to contribute towards PKR homodimer formation49,202. We have used the yeast twohybrid assay to understand the interactions between PKR, PACT, and TRBP successfully
and the system is sensitive enough to allow for detecting moderate to subtle changes in
protein interaction affinities68,179,195. As seen in Figure 4.2, the A91E and A92D mutants
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showed a drastic reduction in interaction with PKR, but the L99E mutant showed strong
interaction with PKR. Contrary to M1 mutants, none of the M2 mutations showed any
effect on the PACT-PKR interaction. These results strongly suggest the important role of
alanine 91 and alanine 92 in M1 motif for mediating the interaction between PACT and
PKR.
PACT-PACT interactions are important for PACT mediated PKR activation in
response to stress68,179 and we next examined the effect of the point mutations on
PACT-PACT interactions. The effect of M1 mutations on PACT-PACT interaction was
quite drastic with A91E, A92D, and L99E mutants showing a complete lack of interaction
(Figure 4.3). However, the M2 mutations showed no effect on PACT-PACT interaction
indicating that the PACT-PACT interaction is mainly mediated by the M1 motif. TRBP
interacts with both PACT and PKR to act as an inhibitor of PKR and the TRBP-PACT
interaction regulates PACT’s ability to activate PKR in a negative manner during stress
signaling. Our results shown in Figure 4.4 indicate that the TRBP-PACT interaction is
mainly mediated by PACT’s M1 motif as the A91E, A92D, and L99E mutations resulted in
a complete lack of TRBP-PACT interaction. The M2 motif mutations A184E, A185E, and
F192E had no effect on the TRBP-PACT interaction. These results indicate that similar to
PACT-PACT interaction shown in Figure 4.4, the TRBP-PACT interaction is also mediated
mainly by the M1 motif in PACT.
Our previous results had indicated that the stress-induced PKR activation by
PACT is dependent on efficient PACT-PACT interactions and the stress-induced
phosphorylation at serine 287 of PACT enhances PACT-PACT and PACT-PKR interactions
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while decreasing TRBP-PACT interactions195. Since the L99E mutant retains its ability to
interact efficiently with PKR but loses its ability for PACT-PACT interactions, we wanted
to create a triple mutant by combining the L99E mutation with phosphomimetic S246D
and S287D mutations. The phosphomimetic S246D and S287D double mutant (DD
mutant) activates PKR in the absence of stress signals, induces apoptosis, and shows
enhanced PACT-PACT and PACT-PKR interactions60,62,91,195. Thus, we wanted to test if the
DD mutation, when combined with the L99E mutation will promote PACT-PACT
interactions. We used the mammalian two-hybrid assay to test this and the results are
shown in Fig. 4.5 A. The wild type PACT shows good PACT-PACT interaction and the L99E
mutant shows no PACT-PACT interaction above the EV control. The DD mutant shows
enhanced PACT-PACT interaction as compared to wild type PACT and in contrast to this,
the combined triple mutant DD-L99E shows a lack of PACT-PACT interaction. This
allowed us to examine if the phosphomimetic DD mutant would promote apoptosis if it
lacked the PACT-PACT interactions.
In order to understand the contribution of PACT-PACT interactions towards
PACT mediated PKR activation, we performed the apoptosis assay using nuclear
condensation as a marker of apoptotic cells. We overexpressed the wild type PACT,
DD mutant, and DD-L99E mutant in HeLa cells and assayed for apoptosis induction.
The overexpression of both wild type and DD mutant PACT proteins is known to
induce apoptosis in the absence of any stress signals. As seen in Fig. 4.5 B, an
overexpression of wtPACT induced apoptosis in about 25% of the cells as compared
to the 5% apoptosis in empty vector transfected cell. The overexpression of the DD
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mutant caused apoptosis in about 36% cells and in contrast to this, the
overexpression of DD-L99E mutant showed apoptosis in only 8% of the transfected
cells. These results indicate that the PACT-PACT interaction is crucial for induction of
apoptosis and the lack of PACT-PACT interactions inactivate PACT’s ability to activate
PKR. These results underscore the importance of enhanced PACT-PACT interactions
in response to stress signals.

4.5 DISCUSSION
In this report, we investigated the role of conserved residues within the M1 and
M2 motifs in PACT towards dsRNA-binding, and interaction with PKR, TRBP and PACT.
Overall, M1 motif plays a more significant role in dsRNA-binding activity of PACT. Similar
to the two lysines at positions 60 and 150 in PKR, the corresponding lysines at positions
84 and 177 showed an essential role in dsRNA-binding. The lysine 88 mutation also
showed a significant reduction in dsRNA-binding similar to the corresponding lysine 64
mutation in PKR. However, the lysine 181 mutation in M2 motif of PACT showed a much
smaller reduction in dsRNA-binding as compared to a drastic effect of corresponding
lysine 154 mutation in PKR.
These results indicate that although the dsRBMs are well conserved in various
members of this diverse family of proteins, the effect of individual analogous point
mutations in various motifs in the context of whole proteins needs to be examined in a
case by case manner. Certain hydrophobic residues in M1 motif (alanine 91, alanine 92,
and leucine 99) as well as in motif 2 (alanine 184) play an important role in dsRNA-
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binding, similar to alanine 68 in M1 and alanine 158 in M2 of PKR202. When we tested
the dsRNA-binding of individual M1 or M2 motifs previously, both M1 and M2 showed
strong dsRNA-binding activity63. The data presented here underscores the importance of
testing the effect of point mutations in the whole protein context instead of individual
domains. The M2 motif, although fully capable of binding dsRNA on its own when
existing as a separate domain, plays an auxiliary role towards dsRNA-binding in the PACT
protein as a whole. Many members of the family of proteins have multiple dsRBMs
present in tandem similar to PACT, TRBP, and PKR196. The dsRBM is known to be a
versatile motif and the individual dsRBMs present in the same protein are known to
have properties that differ in terms of dsRNA-binding and dimerization/multimerization
contributing to their unique contribution to the functionality of the whole protein 203.
An investigation of the relative contribution of the hydrophobic residues in M1
and M2 motifs to the protein-protein interactions demonstrated that M1 motif
contributes maximally for the PKR-PACT, PACT-PACT, and PACT-TRBP interactions. All
three residues (alanine 91, alanine 92, and leucine 99) were indispensable for PACTPACT and PACT-TRBP interactions. In contrast to this, for the PKR-PACT interactions, the
mutation of leucine 99 showed no effect and the alanine 91 and alanine 92 mutations
showed a slight reduction in interaction. The M2 mutations showed no effect on any of
the interactions. These results indicate that either of the M1 or M2 motifs can
effectively mediate the interaction between PKR and PACT. In future, it may be
interesting to test the effects of double mutants in M1 and M2 motifs on PKR-PACT
interactions. The observation that M1 mutations had similar effect on PACT-PACT and
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PACT-TRBP interactions indicates that the individual PACT molecules in cells would
either be present as heteromeric complexes with TRBP or as homomeric PACT-PACT
complexes. However, if the two proteins are capable of forming multimers, it remains to
be determined if the stoichiometry of such complexes may change in response to stress
signals to change the biological consequence and alter survival versus apoptosis
equilibria.
Our previous results demonstrated that a phosphomimetic mutant of PACT
with an aspartic acid substitution at both serines 246 and 287 (DD mutant) shows
enhanced PACT-PACT interactions as compared to wild type PACT indicating that
PACT-PACT interaction promotes PACT-PKR interaction and consequently PKR
activation68. Thus, we further investigated if PACT-PACT interaction may be essential
for PACT’s ability to activate PKR and induce apoptosis by generating a triple mutant
where we combined the DD mutation with L99E mutation. L99E mutation disables
PACT-PACT interactions but keeps the PKR-PACT interaction intact and we previously
have demonstrated that the L99E mutant was unable to activate PKR68. Thus, the
triple mutant (S246D, S287D, L99E) allowed us to test if the phosphomimetic mutant
could activate PKR if it cannot form PACT-PACT interactions.
The inability of the triple mutant to show interaction in mammalian cells as
well as its inability to induce apoptosis, underscores the importance of PACT-PACT
interactions in PKR activation. These results are very significant for understanding the
stress-induced signaling pathways leading to apoptosis since they add an additional
layer of complexity brought about by phosphorylation-mediated changes in the
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relative affinity of various binding partners within the dsRBM family. This is an aspect
that has not been explored to date and can have a significant influence on the
various biological processes regulated by the dsRBM containing proteins176,196.
The essential role of PKR dimerization in activating its kinase function has been
established in many studies when dsRNA is the activating agent177,204,205. PKR activation
is brought about mainly when two PKR molecules bind to a single dsRNA molecule140,206.
PKR’s second dsRBM motif interacts with the catalytic domain to keep PKR in a closed
conformation that prevents ATP binding50,207. Binding to dsRNA induces a
conformational change that releases the dsRBM from the catalytic domain, thus
allowing for ATP-binding. Structural and biophysical data also indicates that dsRNA
principally functions to induce dimerization of PKR via the kinase domain 208. Although
PKR exists in an equilibrium between monomeric and dimeric states in the absence of its
interaction with dsRNA, binding to dsRNA shifts this equilibrium towards the dimeric
form and also induces a conformational change necessary to relieve the
autoinhibition209.
In contrast to this, activated PKR phosphorylated on several serines and
threonines exists in monomeric as well as dimeric forms and both forms are competent
in kinase function and active in phosphorylating eIF2α210. Similar to dsRNA mechanisms,
it is likely that two or more molecules of PKR are brought in close proximity by virtue of
their interaction with PACT dimer or multimer. Thus, PACT may serve the same function
that a dsRNA molecule of sufficient length serves, which is to allow for binding of two
PKR molecules to promote trans-autophosphorylation. It is interesting to note that
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PACT-PKR interaction is strongest when PKR is not catalytically active and PACT interacts
much weakly with catalytically active PKR. PKR activation thus seems to dissociate PACT
from PKR. In future, it will be interesting to study if protein-protein interactions play
similar regulatory roles in RNAi69,70,72, and innate immunity73 pathways that are
regulated by PACT.

.
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Figure 4.1: Mutations in conserved amino acids in PACT’s M1 and M2 dsRNA
binding motifs (dsRBMs) disrupt PACT’s interaction with dsRNA.
(A) Schematic representation of PACT’s domain structure and conserved amino
residues in PACT’s M1 and M2 dsRBMs. Gray boxes represent PACT’s dsRNA binding
M1 and M2 motifs, while the blue box represents PACT’s M3 motif which does not
interact with dsRNA, but is essential for PKR activation by PACT. Conserved residues
in PACT’s M1 and M2 motifs are displayed; residues in red were mutated for this
study.
(B) Sequence alignment of PACT, TRBP, and PKR’s dsRNA binding motifs. The three
conserved dsRBMs of PACT (PACT M1, PACT M2, PACT M3) are aligned to those of
TRBP (TRBP M1, TRBP M2, TRBP M3) and PKR (PKR M1, PKR M2). Amino acid residues
in bold are conserved residues present in all 8 dsRBMs or conservative changes from
the consensus sequence below. Note the presence of several hydrophobic amino
acid residues (AA---AL—L) in all 8 dsRBMs which are known to be important in
mediating each protein’s homodimer and heterodimer interactions and with dsRNA.
(C) dsRNA binding assay. The dsRNA binding activity of each M1 and M2 PACT point
mutant was compared to that of wt PACT using a poly(I).poly(C)-agarose binding
assay with in vitro translated 35S-labeled proteins. 35S-labeled in vitro translated
firefly luciferase protein was used as a control to demonstrate specific PACT
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interaction with poly(I).poly(C). T represents the total input, while B represents the
proteins still bound to poly(I).poly(C)-agarose beads after washes.
(D) Quantification of the dsRNA binding assay. Band intensities of the total and
bound proteins were quantified by phosphorimager analysis, and % dsRNA binding
was calculated for each PACT protein. % dsRNA-binding averages from four
independent experiments are plotted as bar graphs ± S.D.
One-way ANOVA followed by post-hoc Tukey test showed a statistically significant
difference between wt PACT dsRNA binding and that of each of the PACT mutants. P
value wt PACT vs. K84A, K88E, A91E, A92D, L99E, K177E, and K184E PACT mutants =
0.000013, P-value wt PACT vs. K181E PACT mutant = 0.000198, P-value wt PACT vs.
A185E PACT mutant = 0.000014, and P-value wt PACT vs. F192E PACT = 0.000078
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Figure 4.2: Mutations of specific hydrophobic residues in PACT’s M1 dsRBM disrupt PACT’s interaction with PKR. The K296R
PKR/pGBT9 yeast expression vector and PACT M1 and M2 mutants in the pGADT7 yeast expression vector were co-transformed into
AH109 yeast cells. Co-transformants were selected on SD double dropout media (-Tryptophan, - Leucine). 10 microliters of the
transformed yeast cells (OD600 = 10, 1, 0.1. 0.01) were spotted on SD triple dropout media agar plates (-Tryptophan, -Leucine, Histidine). Plates were incubated at 30oC for 4 days. AH109 cells were co-transformed with wt PACT/pGADT7 and K296R PKR/pGBT9
expression vectors as a positive control, and with either the A91E PACT/pGADT7, A92D PACT/pGADT7, L99E PACT/pGADT7, A184E
PACT/pGADT7, A185E PACT/pGADT7, or F192E PACT/pGADT7 and pGBKT7 expression vector as negative controls.
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Figure 4.3: Mutations of hydrophobic residues in PACT’s M1 dsRBM disrupt PACT-PACT homodimer interaction. Each M1 and
M2 PACT point mutant in the pGBKT7 and pGADT7 yeast expression vectors were co-transformed into AH109 yeast cells, and
successfully co-transformed yeast cells were selected on SD double dropout media (-Tryptophan, - Leucine). 10 microliters of the
transformed yeast cells (OD600 = 10, 1, 0.1. 0.01) were spotted on SD triple dropout media agar plates (-Tryptophan, -Leucine, Histidine) containing 10mM 3-amino-1,2,4-triazole (3-AT). Plates were incubated at 30oC for 4 days. AH109 cells were also cotransformed with wt PACT/PGBKT7 and wt PACT/pGADT7 as a positive control, and with either A91E PACT/pGADT7, A92D
PACT/pGADT7, L99E PACT/pGADT7, A184E PACT/pGADT7, A185E PACT/pGADT7, or F192E PACT/pGADT7 and pGBKT7 as negative
controls.
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Figure 4.4: Hydrophobic residue mutations in PACT’s M1 dsRBM disrupt PACT-TRBP heterodimer interaction. AH109 cells were
co-transformed with the TRBP/pGBKT7 yeast expression vectors and each of the previously described PACT M1 and M2 point
mutants in the pGADT7 yeast expression vector. Co-transformed yeast cells were selected on SD double dropout media (Tryptophan, - Leucine). 10 microliters of serial dilutions (OD600 = 10, 1, 0.1. 0.01) of the yeast cells were spotted on SD triple
dropout media agar plates (-Tryptophan, -Leucine, -Histidine) containing 10mM 3-amino-1,2,4-triazole (3-AT). Plates were
incubated at 30oC for 4 days. AH109 yeast cells co-transformed with TRBP/pGBKT7 and wt PACT/pGADT7 served as the positive
control, while AH109 cells co-transformed with either A91E PACT/pGADT7, A92D PACT/pGADT7, L99E PACT/pGADT7, A184E
PACT/pGADT7, A185E PACT/pGADT7, or F192E PACT/pGADT7 and pGBKT7 were negative controls.

Figure 4.5: PACT homodimer interaction is required for stressinduced PACT-PACT interaction and PACT- mediated apoptotic
induction.
(A) The phosphomimetic point mutation is unable to rescue L99E
PACT’s homodimerization defect. COS-1 cells were transfected
with 200 ng each of the indicated GAL4 DBD and VP16 AD
construct pairs, 200 ng of the pG5 Luc reporter construct, as well
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Figure 4.5 (continued) as 1ng of the pRL-Null construct to
normalize for different transfection efficiencies. Cells were
harvested 24 hours after transfection, and lysates were assayed
for Firefly and Renilla luciferase activity. Experiments were
performed thrice in triplicate, and the bars represent the averages
of the experiments ± S.D. Student’s t tests were performed to
determine statistical significance – asterisk * P-value = 0.0027,
double asterisk **P-value = 0.000764, triple asterisk *** P-value =
0.015, # P-value = 0.001158.
(B) Loss of PACT homodimer interaction significantly weakens the
induction of apoptosis due to PACT phosphorylation. HeLaM cells
were transfected with 200ng of pEFPC1 and 300ng of Flag wt
PACT/pCMV2 (wtPACT), 300ng of the phosphomimetic PACT
expression construct (Flag DD PACT/pcDNA 3.1- (DD)) or 300 ng of
the PACT triple mutant construct (Flag L99E DD PACT/ pcDNA 3.1(DD-L99E)). Cells were also transfected with 300 ng of BSIIKS+ and
200 ng of pEGFPC1 (EV) as a control. The cells were observed for
GFP expression 24 hours after transfection, and at least 300 GFP
positive cells were scored as non-apoptotic or apoptotic based on
nuclear condensation indicated by intense DAPI staining. The
percentage of apoptotic cells (% Apoptosis) was calculated using the
formula: (EGFP- expressing cells with intense DAPI nuclear
staining/Total EGFP-expressing cells) x 100. Bars represent averages
± S.D. from three independent experiments. Student’s t tests were
performed to determine statistical significance – ns: not significant,
* asterisk: P-value of 0.0391, ** double asterisk: P-value of 0.00294.
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CHAPTER 5

GENERAL DISCUSSION
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This dissertation focused on the various mechanisms through which the
interferon-induced eIF2α kinase, PKR, is regulated during viral infection and oxidative
stress via its interactions with the dsRNA binding proteins, PACT and TRBP. This
dissertation also underscored the importance of both of PACT’s M1 and M2 dsRBMs in
mediating efficient PACT homodimerization, PACT-TRBP and PACT-PKR
heterodimerization, and consequently PKR activation during cellular stress.
In Chapter 2, we demonstrated that PACT, which normally acts as a cellular
activator of PKR during non-viral cellular stress, is co-opted by the HIV-1 virus to subvert
PKR’s antiviral activity through the formation of a PKR-inhibitory complex that includes
ADAR1, Tat, and dsRNA-containing HIV-1 transcripts. While we have established that
ADAR1 suppresses PACT’s PKR activating function during HIV-1 infection, the effects of
the observed increased ADAR - PACT interaction on potential viral infection-induced
PACT phosphorylation have yet to be elucidated. In vivo 32P orthophosphate labelling of
PACT over the course of infection in cells could establish if PACT is phosphorylated in
virally infected cells, and if ADAR1 precludes this phosphorylation and consequent PACTmediated-PKR activation. As both ADAR1 and PACT contain dsRBMs which are known to
mediate both dsRNA and protein-protein interactions, determination of the essential
dsRBMs and residues in each protein responsible for their interaction can facilitate
peptide-mediated disruption of PACT-ADAR1 interaction during HIV-infection and
enhance PKR-mediated inhibition of viral replication in infected cells. This would be an
exciting novel therapeutic approach in the combinatorial therapy options used currently
for HIV patients.
138

In Chapter 3, we examined the functional importance of TRBP phosphorylation
on TRBP’s homomeric interactions as well as its heteromeric interactions with PKR, and
consequently, on PKR inhibition and cell fate during oxidative stress. Our work
established for the first time that TRBP is phosphorylated in response to oxidative stress
and consequently exhibits increased interaction with PKR to limit the negative effects of
sustained PKR activation and ensure cellular recovery. Since TRBP phosphorylation by
ERK has been shown to stimulate the expression of pro-growth miRNAs and enhance
the stability of the RNA induced silencing complex181, an investigation into any TRBP
phosphorylation dependent alterations of miRNA profiles in response to stress signals
may reveal an additional layer of TRBP mediated modulation of the cellular stress
response independent of PKR and translational inhibition.
In Chapter 4, we determined the relative contributions of each of PACT’s dsRNA
binding motifs to the entire protein’s interactions with dsRNA, with itself, as well as with
PKR and TRBP. Our experiments established that while both dsRBMs mediate dsRNA
interaction, PACT’s M1 motif is important for heterodimeric interactions with TRBP and
PKR and PACT-PACT homodimer formation and highlight the critical role that stressinduced PACT phosphorylation and PACT-PACT homodimerization plays in ensuring a
timely PKR activation in response to various stress. Future experiments can be
performed to determine the importance of PACT homodimerization in various cellular
processes in which PACT has been shown or suggested to play an important role such as
the innate immune response through ADAR1 and the cytoplasmic RNA sensor RIG-I and
RNA interference through interactions with Dicer and TRBP.
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This work emphasizes the importance of stress-induced alterations in the
interactions between these three dsRNA binding proteins in restoring cellular
homeostasis after cellular stress, particularly in light of the fact that all three proteins
are at the intersection of the cellular response to viral and non-viral stress, innate
immunity and small RNA biogenesis.
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